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ABSTRACT
Preterm birth (PTB) is the major determinant of perinatal morbidity and mortality,
and accounts for the second most common cause of neonatal death across the world.
Approximately, one in every ten newborns is born prematurely (before 37 completed weeks
of gestation) amounting to an estimated global 15 million premature births every year.
Preterm neonates are vulnerable to a wide range of short and long term metabolic,
infectious, neurological, and respiratory morbidities. PTB is characterized by different
complex multifactorial process manifested by diverse pathogenetic mechanisms. Despite
many efforts to understand the timing of parturition, the molecular mechanisms through
which PTB is triggered are not fully understood.
Pregnant women with different hepatic dysfunctions like nonalcoholic fatty liver
disease, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy (ICP),
hepatitis B virus, hepatitis C virus, jaundice, and drugs induced liver injuries are at
increased risk of PTB. Amongst these liver disorders, ICP is the most common pregnancyspecific liver disease and typically develops in the late second trimester or early third
trimester of pregnancy. In manuscript 1, the purpose of the study was to investigate whether
dysregulation of bile acid (BA) increases the risk for PTB, and to identify whether it is the
liver injury itself or the elevated serum BA which directly induces PTB. Bile acids (BAs)
are considered as signaling molecules involved in the regulation of various metabolic and
cellular activities. Dysregulation of BAs has been identified as a causative factor for the
induction of various diseases. But so far it has not been directly linked to the etiology of
PTB. In this study, we successfully induced PTB in mice with liver injuries and
dysregulated BAs. In addition, BA administration induced PTB in mice without causing
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liver toxicities, and serum BA levels directly correlated with the rates of PTB. Of
importance, we also identified that it was the elevated BA not the liver injury by itself that
induced PTB. Furthermore, the rates of PTB and survival of newborns were markedly
improved by restoring BA homeostasis through farnesoid X receptor (FXR) activation. The
findings thus establish a direct etiological link between BA and PTB in pregnant subjects
with liver dysfunctions and holds a great promise to develop therapies to either prevent or
delay PTB in pregnant women vulnerable to PTB.
In manuscript 2, we present a novel potential mechanism by which BA induce PTB
through Takeda G-protein receptor-5 (TGR5) regulated C5a/C5aR1 signaling pathway.
Although, the association between elevated maternal serum total bile acid (sTBA) and PTB
has been previously established, but the underlying mechanism how BA trigger PTB is
lacking. The best characterized receptors amongst the bile acid activated receptor (BAR)
are FXR and TGR5. Although FXR (-/-) mice gave birth in the normal range of gestation,
the G.Ds were significantly reduced compared to WT mice, a PTB-like phenotype. Such
PTB-like phenotype is consistent with elevated sTBA levels in FXR (-/-) mice. The results
thus indicate that it is unlikely that BA induce PTB through FXR. On the other hand, TGR5
antagonist SBI-115 induced PTB, indicating that BA induces PTB via TGR5. Moreover,
incubation of human and mouse myometrium with C5a has been demonstrated previously,
that C5a is a uterotonic agent. In addition, C5aR1(-/-) mice were protected against LPSinduced miscarriage. However, the role of C5a/C5aR1 signaling pathway in BA induced
PTB is unknown. In this study, we investigated the effect of cholic acid (CA) on TGR5
and C5aR1 expression in vivo in mice and in vitro in myometrial and endometrial cells.
We found that CA had minimal effects on the overall expression of TGR5 both in vivo and
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in vitro. On the other hand, CA significantly increased the mRNA and protein expression
levels of C5aR1 both in vivo and in vitro. Similarly, the serum and amniotic fluid (A.F)
concentrations of C5a, and serum concentration of IL-6 were markedly increased in CA
treated mice. In addition, CA and SBI-115 treatments increased the mRNA and proteins
expressions of C5aR1 and cAMP concentrations in vitro. On the contrary, treatment with
TGR5 agonist CCDC in vitro decreased the mRNA and proteins expressions of C5aR1 and
cAMP concentrations. Taken together, it was concluded that elevated BA concentration
induced PTB via TGR5 regulated C5a/C5aR1 signaling pathway which in response
induced inflammatory responses via IL-6. Modulating C5a/C5aR1 signaling pathway may
represent a new approach to develop therapies to prevent or delay PTB in pregnant women
with liver disorders.
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PREFACE
This dissertation was prepared following manuscript format. It is divided into two
manuscripts focusing on preterm birth (PTB). The first manuscript centers the impact of
BA dysregulation due to liver disorders on PTB. The etiology of PTB was explored in mice
with either dysregulated BAs or liver injuries. In addition, PTB was induced in a dose
dependent manner by BA administration without causing liver injuries. The second
manuscript investigates the underlying mechanism how elevated BA induces PTB. This
manuscript identified that BA induced PTB via TGR5 activation and its downstream
C5a/C5aR1 signaling pathway. The first manuscript has been published in Nature
Communications in 2020. The second manuscript is still in progress and will be submitted
to a suitable journal once it is completed.
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ABSTRACT
Pregnant women with various liver dysfunctions are at increased risk of PTB due
to dysregulation of bile acids (BAs). BAs are considered as signaling molecules involved
in the regulation of different metabolic and cellular activities. Dysregulation of BAs has
been identified as a causative factor for the induction of several diseases. But so far it has
not been linked to the etiology of PTB. Currently, our understanding on the underlying
mechanisms for PTB is limited. In this study, we successfully induced PTB in mice with
liver injuries and dysregulated BAs. In addition, BA administration induced PTB in mice
without causing liver toxicities, and serum BA levels directly correlated with the rates of
PTB. Of importance, we also identified that it was the elevated BA not the liver injury by
itself that induced PTB. Furthermore, the rates of PTB and survival of newborns were
markedly improved by restoring BA homeostasis through FXR activation. The findings
thus establish the direct etiological link between BAs and PTB in pregnant subjects with
liver dysfunctions and holds a great promise to develop therapies to prevent or delay PTB
in pregnant women with liver dysfunctions.
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INTRODUCTION
The World Health Organization (WHO) defines preterm birth (PTB) as births
before 37 completed weeks of gestation or fewer than 259 days from the first date of a
woman's last menstrual period (1). PTB is further subdivided on the basis of gestational age
as extremely preterm (<28 weeks), very preterm (28-<32 weeks), and moderate or late
preterm (32-<37 completed weeks of gestation) (2). PTB occurs as a result of the failure of
a gestation to reach a certain length of time, rather than by the presence of specific signs or
symptoms

(3)

. PTB continues to present a challenging problem for obstetricians and

pediatricians as it is the major determinant of perinatal morbidity and mortality

(4)

. PTB

remains the second most common cause of neonatal death across the world, and the most
common cause of infant mortality in middle- and high-income economies

(5)

.

Approximately, one in every ten newborns is born prematurely (before 37 completed weeks
of gestation) amounting to an estimated global 15 million new preterm births every year
(6)

. PTB accounts for 11% of births worldwide (7-9). In United States, the rate of PTB is one

out of ten newborns which keeps increasing with unidentified reasons (10, 11). It is the most
significant clinical issue in contemporary obstetrics (12) accounting for 5–18% of deliveries
globally (13).
PTB has lifelong health outcomes

(10)

. Preterm neonates are vulnerable to wide

range of short and long term metabolic, infectious, neurological and respiratory morbidities
and the consequences of these adverse outcomes are apparent at lower gestational ages (14).
These consequences also persist from early childhood into adolescence and adulthood (15,
16)

. PTB is characterized by a variety of causes and is usually categorized into iatrogenic

and spontaneous PTB depending on the nature of the underlying factors. Iatrogenic or
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provider-initiated preterm birth is defined as induction of labor or elective caesarean birth
before 37 completed weeks of gestation for maternal or fetal indications due to urgent
medical or non-medical reasons

(12)

while, spontaneous PTB occurs before 37 weeks of

gestation due to spontaneous onset of labor or premature rupture of membranes (17).
PTB is characterized by different complex multifactorial process manifested by
diverse pathogenetic mechanisms

(18)

. Although various risk factors associated with PTB

have been reported, the majority of PTB cases have no obvious causes

(7)

. Despite many

efforts to understand the timing of parturition, the molecular mechanisms through which
PTB is triggered are not fully understood. As a result, the current available treatment
approaches to prevent PTB are not very effective or indicate inconsistent benefits

(19, 20)

.

The primary focus of current management is on the prevention of PTB (21, 22).
The liver plays a key role in both maternal and fetal wellbeing (23). If the function
of liver is compromised, dysregulation of bile acids (BAs) occurs. BAs are signaling
molecules which regulate a variety of cellular and metabolic activities

(24-26)

. These

pleiotropic molecules are predominantly produced in the liver by utilizing cholesterol as
their chemical backbone. Majority of BAs secreted into the duodenum from the liver are
taken up by the ileum through active transport, secreted into the blood and recirculated
back to the liver. With impaired liver functional capacity, BAs tends to increase (27, 28) due
to the release of BAs from damaged hepatocytes as well as impaired BA disposition.
Pregnant women with different hepatic dysfunctions like nonalcoholic fatty liver
disease (NAFLD) (29) , acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy
(ICP) (30-32), hepatitis B virus (HBV) (33), hepatitis C virus (HCV) (34), jaundice (35) and drugs
induced liver injuries are at increased risk of PTB. Amongst these liver disorders is

7

cholestasis in which normal bile flow is either disrupted or reduce which leads to
intrahepatic accumulation of BAs (36).
ICP is a reversible cholestasis (37) and is the most common pregnancy-specific liver
disease

(38)

and typically develops in the late second trimester

(39)

or occurs in the third

trimester of pregnancy. ICP patients have abnormal values of hepatobiliary-injury
biomarkers as well as raised concentration of serum bile acid (sBA)

(40)

that resolve

typically by twelve weeks postpartum. Adverse pregnancy outcomes occur more
commonly when maternal sBA concentration is >40µmol/L. Although, once maternal sBA
levels exceed 10µmol/L, the patient is diagnosed as ICP. Maternal sBA concentration is
used to classify the severity of ICP. An sBA level between 10 to 39µmol/L is considered
as mild ICP, 40 to 99 µmol/L corresponds to moderate ICP and ≥100µmol/L is considered
as severe ICP.
Despite current available treatments, the rate of PTB is twice in ICP compared to
normal pregnancies and the fetal demise ranges between 2 to 11%

(41)

. Pregnant women

with other liver diseases or injuries also exhibited increased rates of PTB. Thus, we
hypothesized that impaired liver function due to liver disorders increases the risk for PTB.
In addition, various liver dysfunctions produce significantly higher odds of serious
maternal and perinatal complications (42). So far, the effects of cholestasis and other liver
impairments on the outcome of pregnancy in rodent models has not been established. Here,
we investigated for the first time the effects of two liver disorder models on PTB including
estrogen-induced cholestasis for ICP and CCl4-induced liver injury for general liver
disorders. We identified that EE2 induced cholestasis or CCl4 induced liver injuries not
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only induced PTB in pregnant mice due to BA dysregulation but also exerted detrimental
effects on fetal survival rates.
Dysregulation of BA has been identified as a causative factor for the induction of
various diseases. But so far it has not been linked to the etiology of PTB. Although, some
studies have reported the association of elevated maternal sTBA with PTB (30, 31, 43) but the
mechanistic and direct etiological link between BAs and PTB has not been established.
Moreover, it remains to be determined whether liver injury itself or elevated BAs because
of compromised liver function trigger PTB. Thus, we hypothesized that elevated maternal
sBA is the direct triggering factor for the induction of PTB and not the liver injury by itself.
We investigated the effect of BA supplementation in pregnant mice and found that BA
induced PTB without causing any liver toxicities.
Enterohepatic circulation of BA is under tight regulation by nuclear receptor
signaling, notably farnesoid X receptor (FXR)

(44)

. Activation of FXR by BAs result in

reduced BA synthesis and enhances BA disposition

(45, 46)

. It is evident that the FXR

agonist, GW4064 protects against cholestatic liver damage in a rat model and results in
significant reduction in liver damage

(44)

. Here, we hypothesized that restoring BA

homeostasis by FXR activation will prevent or delay PTB in pregnant subjects whose liver
function is impaired. Treatment of pregnant mice with synthetic FXR agonist not only
delayed PTB but also enhanced liver functional capacity by restoring BA homoeostasis via
FXR activation, and hence improved the survival rate of newborns in pregnant mice.
In present study, PTB was successfully reproduced either by EE2 induced
cholestasis or CCl4 induced liver injuries. More importantly, present study for the first time
induced PTB by BA supplementation and established a direct etiological link between BA
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and PTB. Taken together, these findings will pave the way for the development of
mechanism-based therapies to either prevent or delay PTB.

MATERIAL AND METHOD
Chemicals and Reagents: CA, CCl4, EE2 and olive oil were purchased from SigmaAldrich. FXR agonist GW4064 was purchased from AdooQ Bioscience. 1,2 propanediol
and corn oil were purchased from Acros organics. Mouse TBA kits was purchased from
Crystal Chem and Mouse AST kits were purchased from Biovision. DY268 was purchased
from Axon MEDCHEM. Paraformaldehyde solution (4% in PBS) was purchased from
Santa Cruz Biotechnology.

Mouse Models for PTB with Liver Injuries: CD-1 male and female mice between the
age of 5 and 8 weeks were purchased from Charles River Laboratory (Wilmington, MA).
After acclimatization for 1-week, female mice were mated overnight with male mice to
achieve timed pregnancy. Next morning male mice were separated from female and this
day was considered gestation day (G.D 0). On G.D 16.3, one group of female mice (n=12)
were treated with EE2 subcutaneously once daily at a dose of 25 mg kg-1 in a solution of
80 % 1,2-propanediol and 0.15% NaCl and this treatment was continued until initial of
labor. Similarly, single intraperitoneal injection of CCl4 was administered to another group
of pregnant mice (n=5) at a dose of 1 mL kg−1, 1.5 mL kg−1 (n=9), or 2 mL kg−1(n=5) in
olive oil (40% v/v) on G.D 16.3. Following CCl4 treatment the mice were closely observed
for labor. The G.Ds and rates of live birth were recorded in both EE2 and CCl4 treated
pregnant mice. The mice were then euthanized once they gave birth. Blood and different
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tissues were collected for characterization and analyses. All mouse studies were performed
with prior approval by the Institutional Animal Care and Use Committee (IACUC) of the
University of Rhode Island with a protocol number: AN09-02-008. All mice had free
access to food and water ad libitum and were kept in ventilated cages in a 12-h light – dark
cycle, control room temperature (20 – 22°C) and relative humidity (40%).

Treatment of Pregnant Mice with Bile Acid CA and FXR Antagonist DY268: Pregnant
mice (n=8) were either treated with 0.5% (w/w) or 1% CA (w/w) n=6) in a regular chow
diet at G.D 15.3 and the treatments were continued until the mice give birth. Another group
of pregnant mice (n=8) were treated with a combination of 0.3% (w/w) CA in diet and FXR
antagonist DY268 at a dose of 20 mg kg−1 through oral gavage twice daily. DY268 was
dissolved in 1,2 propanediol and 1X PBS at a ratio of 1:4. Both 0.3% CA and DY268
treatments were initiated at G.D 15.3 and continued until labor. All pregnant mice were
closely monitored for labor after initiation of the above treatments. G.Ds and the rates of
live birth were recorded. Once the mice give birth, they were euthanized in order to collect
blood and tissue samples for analyses. In addition, non-pregnant mice were either treated
with DY268 at a dose 20 mg kg−1 via oral gavage twice daily or with 0.3% CA in diet for
3 days. The mice were then euthanized, and blood samples were collected for serum total
bile acid (sTBA) and serum aspartate aminotransferase (sAST) assays.

Treatment of Pregnant Mice with a Combination of CCl4 and FXR Agonist GW4064:
In one group of mice (n=13), treatment with FXR agonist GW4064 was initiated on G.D
15.3 through oral gavage twice a day at a dose of 50 mg kg−1 in corn oil. The treatment was
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continued until the mice gave birth. In addition to GW4064 treatment, the mice were also
injected intraperitoneally with a single CCl4 injection at a dose of 1.5 mL kg−1 in 40% olive
oil at G.D 16.3. The mice were closely monitored until labor. The G.Ds and rates of live
birth were recorded. The mice were then euthanized for blood and tissues collection for
analyses.

TaqMan Quantitative Real-Time PCR: RNA bee reagent (RNA-STAT-60, Tel-Test,
Inc,) was used for total RNA extraction. For cDNA synthesis, 2μg of total RNA was mixed
with 1 μl random primers followed by the addition of DEPC treated water to make the final
volume of 13 μL. The primers were annealed to RNA template at 65 °C for 5 minutes
followed by 1 minute incubation on ice. Then, 7μL of RT reaction mix containing 4 μL 5x
SSIV buffer,1 μL 0.1M DDT, 1 μL RNase inhibitor and 1 μL SuperScript IV Reverse
Transcriptase (200 U/μL) was combined to the annealed RNA samples. Then, the
combined reaction mixture was incubated at 23 °C for 10 min followed by 50 °C for 10
min. The reaction was then terminated at 70 °C for 10 min. The cDNA samples were then
diluted six times with autoclaved water. TaqMan universal master mix (Applied
Biosystems) was used for real-time PCR reaction in a total volume of 10 μL, containing 5
μL of universal PCR TaqMan master mix, 1.5 μL of autoclaved water, 0.5 μL of gene
specific TaqMan probe and 3 uL of cDNA templates. Applied Biosystem 7iiA Real-Time
PCR system was used for amplification and quantification. The cycling description was 50
°C for 2 min, 95 °C for 10 min, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C.
The TaqMan assay probes for BSEP (assay ID: Mm00445168_m1), CYP7A1 (assay ID:
Mm00484150_m1),

SHP

(assay

ID:

Mm00442278_m1),
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FXR

(assay

ID:

Mm00436425_m1), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; assay ID:
Mm99999915_g1) were purchased from Applied Biosystems. Transcript levels of BSEP,
CYP7A1, SHP and FXR were normalized against the GAPDH. Validated TaqMan probes
and TaqMan master mixtures were obtained from Applied Biosystems.

Liver Function Tests: Blood samples collected from euthanized mice were subjected to
centrifugation at 2000 rpm for 15 minutes to collect serum samples. Serum TBA assay was
performed according to manufacturer’s instructions. The reaction was initiated by
reconstituting reagent CC3 with 10 mL of reagent CC1. Then, 20 μL of calibrator or serum
samples were mixed with 150 μL of reagent CC3 followed by incubation at 37 °C for 5
minutes. Absorbance (A1) was measured at 540 nm. Then, 30 μL of reagent CC2 was
added to the reaction mixture followed by incubation at 37 °C for 5 minutes. A2 was
measured at 540 nm. Serum TBA concentrations were calculated according to kit’s
instruction. For serum AST detection, the assay reaction was initiated by the addition of 10
μL glutamate standards or serum samples with 40 μL of assay buffer followed by the
addition of 100 μL of reaction mix (prepared per kit instructions). The plate was measured
initially at 450 nm (A1) at T1 (T1 > 10 minutes) and then again (A2) at T2 after incubating
the reaction at 37 °C for 60 minutes. Glutamate standard curve was plotted, and AST
activity or levels were calculated according to kit’s instructions.

Histopathology: Fresh liver tissues were collected form euthanized mice and were fixed
immediately with 4 % paraformaldehyde in PBS. After tissue fixation, the samples were
processed in the Molecular Pathology Core Facility at Brown University for paraffin
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embedding, sectioning, hematoxylin, and eosin staining. The histopathological
examination was performed by a pathologist at the same facility. An unbiased approach
was adopted when the samples were delivered to the Core Facility. The samples were
randomized and blinded, and no information was provided to core facility regarding the
sample treatment groups. The samples were decoded once we received the histopathology
report.

Statistics: For statistical analysis, student’s t test for unpaired comparison (two-sided) was
applied for normally distributed data. The correlation coefficient (r) and associated p values
were determined by Pearson correlation analysis. All the data presented as mean ± SD were
analyzed via GraphPad Prism 9 software and a p value of ≤0.05 was considered statistically
significant.

RESULTS
Estrogen induced cholestasis and PTB in mice.
It has been reported previously that elevation of reproductive hormones especially
estrogen during the late stage of pregnancy contributed to the pathogenesis of ICP

(47-49)

.

In fact, estrogen induced cholestasis in rodents has been a well-established animal model
for ICP

(50, 51)

. However, no studies have been accomplished to explore the effects of

estrogen induced cholestasis outcome of pregnancy in rodent models. Thus, present study
conducted experiments to determine whether estrogen induces cholestasis and resulting
BA dysregulation can reproduce the PTB in mice. As shown in Fig. 1A, PTB was
significantly induced in pregnant mice after treatment with synthetic estrogen 17α-
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ethynylestradiol (EE2) started at G.D 16.3. The mean G.Ds in control mice (n=9) were
decreased significantly from 19.9 ± 0.4 days to 18.76 ± 1.15 days in EE2- treated mice
(n=12) (*p=0.013; Fig. 1A). Among the EE2 treated group, 58.3% mice gave PTB (earlier
than 18.9 days) (**p=0.0068; Fig. 1A). Moreover, it was observed that large proportion of
newborns were dead with a huge variation from mouse to mouse. The rates of live birth in
EE2 treated group ranged from 0% to 91.7% with an average of 34.44 ± 29.78%, which is
significantly lower when compared with control group (****p<0.0001) as shown in Fig.
1A.
Previous reported studies identified that treatment of experimental animals with
EE2 decreased the bile flow, thereby causing accumulation of high levels of BAs along
with abnormal BA composition in the liver (52, 53). Thus, in accord with previous reported
studies, we also observed increase in serum concentration of BA after EE2 treatment

(54)

.

sTBA were significantly elevated (****p<0.0001) from 7.49 ± 2.01 μM in control (n=9)
to 31.91 ± 3.12 μM in EE2 treated mice (n=12) as shown in Fig. 1B. Moreover, it was
observed that sTBA were negatively correlated with both G.Ds (r = −0.644, *p = 0.045)
and the rates of live birth (r = −0.601, *p = 0.030) as shown in Fig. 1B.

Serum AST levels in EE2 induced liver injuries and PTB in mice.
Cholestatic diseases are characterized by toxic BA accumulation and abnormal BA
composition, which subsequently cause liver injury (52). As expected, serum AST which is
a specific biomarker for liver injury (55), was significantly elevated from 17.3 ± 8.5 U L−1
in control (n=9) to 87.3 ± 19.2 U L−1 in EE2 treated mice (****p<0.0001; n=12; Fig. 2A).
Moreover, the serum AST levels correlated negatively with the rates of live birth (r =
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−0.678, *p = 0.015). However, such negative correlation did not observe between serum
AST levels and G.Ds (r = 0.143, p = 0.657) or the sTBA concentrations (r = 0.135, p =
0.675) as shown in Fig. 2A. In addition, no significant correlations were detected between
the rates of live birth and the G.Ds (r = −0.177, p = 0.582; Fig. 2B).

Carbon tetrachloride (CCl4) induced liver injuries and PTB in mice.
To the best of our knowledge, no animal models have been reported for studying
PTB with liver injuries. CCl4 is a well-known hepatotoxic agent that is commonly used to
induce different liver injuries. Thus, present study used CCl4 as a challenging agent to
induce hepatic injury and BA dysregulation and explored its effects on PTB in pregnant
mice. The results revealed that CCl4 dose-dependently induced PTB (Fig. 3A). The mean
G.Ds were significantly reduced from 19.9 ± 0.4 days in control (n=9) to 18.9 ± 1.1
(*p=0.036), 17.9 ± 0.6 (**** p<0.0001), and 17.6 ± 0.6 days (**** p<0.0001) in mice
treated with 1 mL kg−1 of CCl4 (n=5), 1.5 mL kg−1 of CCl4 (n=9), and 2 mL kg−1 of CCl4
(n=5), respectively.
As shown in Fig. 3A, mice treated with 1 mL kg-1 of CCl4 resulted in 60% PTB
while 100% mice gave PTB with the doses of 1.5 mL kg-1 and 2 mL kg−1 of CCl4. The
minimal dose of CCL4 (1.5 mL kg−1) that resulted in 100% PTB was used in subsequent
studies, and the mice in this group were characterized for further analyses. The rates of live
birth were significantly reduced to 26.63 ± 27.82% in mice treated with 1.5 mL kg−1 CCl4
(**** p <0.0001; Fig. 3A). Similarly, sTBAs were markedly elevated (**** p<0.0001)
from 7.49 ± 2.01 μM in control group (n=9) to 27.78 ± 10.02 μM in CCl4 treated group as
shown in Fig. 3B. Moreover, such elevated sTBA concentrations were negatively
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correlated with both G.Ds (r = −0.867, **p = 0.002) and the rates of live birth (r = −0.848,
**p = 0.004) (Fig. 3B).

Elevated serum AST levels in CCl4 -induced liver injuries and PTB in mice.
As mentioned earlier CCl4 is commonly used to induce experimental liver injury in
laboratory animals (56-59). Once the liver is damaged, AST are released into the blood, which
causes increase in serum AST concentration (60). As anticipated, serum AST concentrations
were significantly (**** p<0.0001) elevated from 17.3 ± 8.5 U L−1 in control group (n=9)
to 122.1 ± 22.8 U L−1 in CCl4 treated group (Fig. 4A). Moreover, such elevated serum AST
levels were positively correlated with sTBA concentrations (r = 0.765, *p = 0.016) as
shown in Fig. 4B. However, no significant correlations were identified between serum AST
levels and the G.Ds (r = −0.545, p = 0.147) nor with the rates of live birth (r = −0.489, p =
0.181) as shown in Fig 4A. Interestingly, it was observed that majority of the dead newborn
were from those mice who gave extremely early PTB around G.D 17.5. In addition, a
positive correlation was detected between the rates of live birth and G.Ds (r = 0.967, ***
p<0.001; Fig. 4A).

Bile acid cholic acid (CA) induced PTB in mice.
As, shown in the previous data that a positive correlation between sTBA
concentrations and rates of PTB was observed in mice treated with either EE2 or CCl4.
Thus, we hypothesized that elevated sBAs directly induce PTB. To test this hypothesis,
pregnant mice were treated with a diet containing 0.3%, 0.5% or 1% CA starting at G.D
15.3. As identified in Fig. 5A, CA dose-dependently induced PTB in pregnant mice. The
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average G.Ds were reduced from 19.9 ± 0.5 in the control group (n=9) to 19.4 ± 0.5 in mice
fed with 0.3% CA diet (n=6) and 19.4 ± 0.8 in mice fed with 0.5% CA diet (n=8). However,
such decline in G.Ds did not reach statistical significance despite of the fact that PTB rate
was observed in 33.34% of mice fed with 0.3% CA and 50% in mice fed with 0.5% CA
diet respectively. Interestingly, a rate of 100 % PTB was observed in mice (n=6) fed with
1% CA diet as the G.Ds were significantly reduced to 17.9 ± 0.3 when compared with
control group (**** p<0.0001; Fig. 5A).
Moreover, all the newborns were alive in mice treated with 0.3% CA or 0.5% CA
while, an average of 85.0 ± 10.6% of newborns were alive in the mice fed with 1% CA diet
as shown in Fig. 5B. Similarly, the rates of live birth correlated positively with G.Ds
(r=0.774; ** p=0.002; Fig. 5B). In addition, sTBA concentrations were significantly
elevated in both 0.5% CA and 1% CA treatment groups as shown in Fig. 5C. The average
sTBAs were increased from 7.49 ± 2.01 μM in control mice (n=9) to 17.4 ± 3.3 μM in mice
(n=8) fed with 0.5% CA diet (**** p<0.0001) and 24.9 ± 7.2 μM in mice (n=6) fed with1%
CA diet (**** p<0.0001; Fig 5C). When sTBAs were correlated with both G.Ds and the
rates of live birth, a negative correlation was observed in both G.Ds (r = −0.801,
***p<0.001) and the rates of live birth (r = −0.803, *** p<0.001; Fig. 5C).

Serum AST levels in BA induced PTB in mice.
CA being a mild BA in inducing hepatotoxicity (61), serum AST concentrations were
only slightly elevated from 17.3 ± 8.5 U L−1 in control mice to 22.8 ± 4.6 in mice fed with
0.5% CA diet and 32.1 ± 7.9 U L−1 in mice fed with 1% CA diet (** p=0.006; Fig. 6A). It
is noteworthy that the AST levels observed among all the three groups were within the
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normal physiological range (6 to 48 U L-1) (62), demonstrating that minimal hepatic injury
was induced by CA administration. Correlation analysis revealed that serum AST levels
positively correlated with sTBA concentrations (r=0.957; *** p<0.001) as shown in Fig.
6A. Similarly, serum AST levels negatively correlated with both G.Ds (r=-0.835; ***
p<0.001) and the rates of live birth (r=-0.891; *** p<0.001; Fig. 6B).

Elevated BAs, not liver injury, induced PTB in mice.
As mentioned previously, mice fed with 0.5% CA diet, only 50% of them gave PTB
with negligible hepatic injury as AST levels were comparable with the control mice. The
data identified that it was the elevated BAs, not liver injury, that caused PTB in mice. To
further substantiate such conclusion, the non-pregnant mice were treated with a reduced
CA dose (0.3%) or FXR antagonist DY268 to explore the effects of these treatments on
sTBA and serum AST levels. The rational for DY268 treatment was that FXR antagonism
would increase endogenous BA concentrations via increasing BA synthesis and reducing
BA disposition.
As shown in Fig. 7A, sTBA concentrations were markedly increased in mice fed
with 0.3% CA diet (n=7; **** p<0.0001) or DY268 (n=7; **** p<0.0001) when compared
to the controls (n=9). Despite of elevated sTBA concentrations, serum AST levels did not
increase in both treatment groups (Fig. 7A), indicating that none of the treatment induced
any liver injury. Although, sTBA levels in mice either treated with DY268 or 0.3% CA in
diet were elevated to 13.7 ± 2.4 μM or 14.1 ± 2.6 μM, still this elevation may not be
sufficient to successfully induce PTB based on the previous findings with 0.5% CA
treatment (Fig. 5A and Fig. 5C). Thus, pregnant mice were treated with a combination of
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0.3% CA and DY268. As expected, the average G.Ds were significantly reduced from 19.9
± 0.4 in the control group (n = 9) to 18.3 ± 0.3 in the treatment groups (n = 8) (**** p
<0.001; Fig. 7B). The rates of PTB in pregnant mice treated with the combination of 0.3%
CA and DY268 reached to 87.5% (**** p<0.0001) as shown in Fig. 7B.
In addition, sTBA concentrations were significantly elevated to 22.3 ± 2.8 μM in
the treatment group (****p<0.0001; Fig. 7C), which is markedly higher than the sTBA
concentrations in mice treated with DY268 or 0.3% CA alone (Fig. 7A). On the contrary,
serum AST levels did not change as compared to the control group (Fig. 7D), indicating
that no liver injury was induced by the combination treatment of 0.3% CA and DY268.
This finding is further supported by the histopathological examination of the mice liver
samples which also confirmed no hepatic injury as demonstrated in Fig. 7E. In accord with
the data of pregnant mice fed with 0.5% CA diet (Fig. 5B), all the newborns were alive
(data not shown). Thus, present data established that it was the elevated BAs and not the
livery injury itself that induced PTB.

Prevention of PTB by restoring bile acid homeostasis.
Enterohepatic circulation of BA is under tight regulation by nuclear receptor
signaling, notably FXR (63). Activation of FXR by BAs result in reduced BA synthesis and
enhances its disposition (64, 65). Thus, we hypothesized that restoring BA homeostasis via
FXR activation will prevent PTB. This hypothesis was tested by treating pregnant mice
either with CCl4 alone or a combination of CCl4 and FXR agonist GW4064. As expected
GW4064 treatment markedly increased the G.Ds from 17.9 ± 0.59 in mice treated with
CCl4 (n = 9) to 19.1 ± 0.76 in mice treated with CCl4 and GW4064 (n = 13; *** p<0.0009)
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as shown in Fig. 8A. Moreover, the rates of PTB were significantly reduced from 100% to
38.5% (** p=0.004; Fig. 8A) and the rates of live birth were considerably improved to 91.4
± 20.9% from 25.6 ± 27.8% (**** p<0.0001; Fig. 8A). In addition, sTBA concentrations
were markedly reduced in GW4064 and CCl4 treatment group to 23.8 ± 5.5 μM from 38.3
± 4.1 μM in CCl4 treatment group (**** p<0.0001; Fig. 8B). Not surprisingly, serum AST
levels were significantly reduced in GW4064 treatment group to 43 ± 15.3 U L−1 from
122.1 ± 22.8 U L−1 in CCl4 treated alone group (**** p<0.0001) as shown in Fig. 8B. More
interestingly, a positive correlation was observed between serum AST levels and sTBA
concentrations (r = 0.928, ***p <0.001) as shown in Fig. 8B.
Of note, bile salt export pump (BSEP) is FXR target protein and responsible for the
rate limiting step in the enterohepatic circulation of BA (66). Activation of FXR by GW4064
significantly enhanced the expression of BSEP (**p=0.032; Fig. 8C), indicating enhanced
biliary BA disposition. On the contrary, cholesterol 7α-hydroxylase (CYP7A1), a ratelimiting enzyme for BA synthesis, was significantly downregulated in GW4064 treatment
group when compared to CCl4 treatment group (**p=0.0092; Fig. 8C), suggesting reduced
BA synthesis. Considering that, FXR also directly regulates gene expression notably via
the induction of transcription factors like small heterodimer partner (SHP) transcription (67)
which is a repressor of CYP7A1 , GW4064 treatment significantly increased the expression
of SHP as compared to CCl4 group (*p=0.0141; Fig. 8D). However, GW4064 treatment
did not show any significant effects on FXR expression as shown in Fig. 8D.
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Correlation analyses in mice treated with a combination of CCl4 and GW4064.
Correlation analysis (Fig. 9A) showed that sTBA concentrations negatively
correlated (r = -0.775, **p =0.005) with G.Ds in mice treated with a combination of CCl4
and GW4064. However, such negative correlation did not reach a significance level when
sTBA levels were compared to rates of live birth (r = -0.589, p =0.073) as shown in Fig.
9A. On the other hand, serum AST levels negatively correlated with both G.Ds (r = -0.725,
*p =0.012) and the rates of live birth (r = -0.661, *p =0.038) as shown in Fig. 9B. Moreover,
a direct positive correlation was also detected between the G.Ds and the rates of live birth
(r = 0.648, *p =0.043; Fig. 9C).

DISCUSSION
The occurrence of PTB and its related complexities remain a serious challenge due
to the fact that the underlying pathophysiological mechanisms by which PTB is induced
are still a mystery

(68)

. Consequently, the contemporary treatment options to delay or

prevent PTB are either ineffective or shown inconsistent effects (69, 70). In the current study,
we investigated the association between BA dysregulation and PTB in pregnant mice.
Under different pathological conditions of liver disorders, BAs levels tend to increase
which may act as a signal of impaired liver to interact with and regulate other organs of the
body. Successful pregnancy requires substantial physiological and metabolic adaptions to
meet the demands of the growing fetus. When the energy requirements from both the fetus
and mother cannot be fulfilled by the impaired liver, pregnancy termination is the preferred
option for the mother to survive

(71)

. In present study, we successfully accomplished the

cause-effect correlation between BA dysregulation and PTB. EE2 induced cholestasis or
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CCl4 caused liver injuries compromised the liver function in pregnant mice, consequently
induced PTB. In addition, we further illustrated that BA treatment effectively and dose
dependently induced PTB in mice. Our findings are in accord with data from previous
reports that sTBA levels were associated with increased risk for PTB in ICP patients (72-74).
The relationship between estrogen and ICP is quite obvious (75) as elevated levels
of estrogen during late stages of pregnancy play a crucial role in the pathogenesis of ICP
(76)

. In present study, we effectively reproduced PTB with EE2 induced liver dysfunction.

Although, various mouse models of PTB have been documented (77), we are the pioneers
to establish EE2 induced cholestasis as animal model for PTB in pregnant mice. It was
observed that majority of the pups born were dead in EE2-induced PTB in mice. Present
findings are in accord with previous reports that identified increased still birth in ICP
patients

(72-74)

. Administration of synthetic ethinyl estradiol is known to increase serum

markers of liver damage. Indeed, when BAs elimination is compromised by the changes in
bile flow from the liver, the accumulation of toxic BAs in the liver causes cholestatic injury
and tissue damage. In the present investigation, in agreement with previous data

(78)

, we

showed that serum AST levels were increased by EE2 administration. In fact, EE2 is widely
used in rodents to investigate molecular mechanisms contributed to estrogen-induced
cholestasis

(79)

. But interestingly, we observed that EE2 induced elevated serum AST

negatively correlated with rates of live birth, indicating that serum AST can potentially
serve as a prognosticate for the fetal health status.
CCl4 has been commonly used to prompt various hepatic injuries in animals
including NAFLD, non-alcoholic steatohepatitis, and fibrosis (80-82). It is evident that CCl4
dysregulate the BA enterohepatic circulation which leads to the intrahepatic accumulation
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of BAs

(83)

. Consistent with previous reported data

(84)

, we also observed that sTBA

concentrations were elevated in CCl4 treated mice when compared with control mice.
Compared with EE2 induced PTB model, serum AST levels were high in CCl4 induced
model of PTB in mice. We noticed that in both mouse models of PTB with liver injuries,
serum AST levels were not directly correlated with the G.Ds. These findings indicate that
serum AST may not serve as a marker for predicting PTB in pregnant women with different
liver disorders. In contrast to EE2 induced model of PTB, serum AST did not correlate with
the rates of live birth in CCl4 model of PTB, suggesting that AST will not be a suitable
prognostic marker for the health status of fetus in pregnant women with liver injuries.
Despite of the fact that mice models of PTB with liver injuries were successfully
accomplished in the present study, the underlying pathophysiological mechanisms in both
models of PTB may differ. In CCl4 induced PTB, the rates of live birth negatively correlated
with the G.Ds. Remarkably, majority of pups born dead with immensely early G.Ds in
CCl4 model. The finding is in line with the clinical data from pregnant women, as higher
fetal mortality rates were observed in extreme early PTB

(85, 86)

. The high rates of dead

born recorded in the EE2 induced model of PTB may serve as the sum of iatrogenic PTB
and stillbirth in ICP patients. Taken together, EE2 induced model of PTB may serve as a
suitable mouse model for studying the pathophysiological aspects of iatrogenic PTB and
stillbirth in ICP patients. On the other hand, CCl4 induced model of PTB may be a good
mouse model to study the pathogenesis of PTB with liver dysfunctions and BA
dysregulation.
In this study, we effectively induced PTB in mice with CA supplemented diet in a
dose dependent manner. Interestingly, we observed that majority of pups born in CA
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induced PTB mice were alive. In addition, in CA induced PTB model, sTBA negatively
correlated with G.Ds, supporting our previous notion that BA is etiologically linked to
PTB. Moreover, negative correlation between sTBA and the rate of live birth is indicative
of adverse effects of high BAs on fetus health. In support of present findings, growing body
of evidence have suggested that elevated fetal BAs may predispose the fetal heart to sudden
arrhythmic events leading to intrauterine death

(87-89)

. Despite of the fact that only slight

elevation in serum AST levels were observed in mice treated with CA supplemented diet,
still the serum AST levels are with in normal physiological range as normal reference value
for serum AST ranges between 6 to 48 U L-1 (62), indicating minimal or no hepatic injuries.
The findings are in line with the finding from a previous report that CA has minimal
potential to induce hepatotoxicity (61).
To further substantiate our hypothesis, that it is the elevated BAs, not hepatic injury,
that triggers PTB, we investigated the effects of a low dose of CA (0.3%) in combination
with FXR antagonist in pregnant mice. As evident in the findings, the combined treatment
induced successfully PTB in mice. Interestingly, the serum AST levels were comparable
with control group, and no hepatic toxicities or injuries were observed in histopathological
examination. The findings thus strongly affirmed that elevated BA is a triggering factor for
the induction of PTB, and not liver injury by itself. In present study we demonstrated that
FXR agonist delayed PTB in CCl4 induced model of PTB, speculating that FXR activation
restored BA homeostasis, and improved the liver functional capacity or promoted liver
repairing process. Supporting such speculation is our data that FXR activation reduced
serum AST and sTBA levels. Taken together, our data demonstrated that FXR agonism not
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only reduced CCl4 induced PTB by restoring BA homeostasis, but also considerably
improved fetal survival rates.
Given the fact that despite considerable research in the setting of ICP to study the
pathophysiological mechanism of PTB, current available treatment options or interventions
to delay or prevent PTB are either ineffective or produced inconsistent benefits. Therefore,
more mechanism-based research is required to fully understand the underlying mechanisms
of PTB. Based on the findings in present study, restoring BA homeostasis via FXR
activation, FXR agonists warrants new treatment options to prevent or delay PTB in
pregnant women with various liver dysfunctions.
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Fig. 1. EE2-induced cholestasis and PTB in mice. (A) The G.Ds, the rates of PTB (%)
and live birth (%) in controls (n = 9) and EE2-treated pregnant mice (n=12). (B) The sTBA
concentrations in controls (n = 9) and EE2-treated mice (n=12) and a negative correlation
between sTBA concentrations and the G.Ds or the rates of live birth (%). Student’s t test
for un-paired comparison (two-sided) and Pearson correlation analysis were applied for
statistical analysis. All the data presented as mean ± SD were analyzed via GraphPad Prism
9 software. A p value of ≤0.05 was considered statistically significant.

Fig. 2. Serum AST levels in EE2-inudced liver injuries and PTB in mice. (A) The serum
AST levels in control (n=9) and EE2-treated mice (n=12) and correlation analyses between
G.Ds and serum AST levels. (B) Correlation analysis between serum AST levels and rates
of live birth (%) or sTBA concentrations. (C) no correlation between the G.Ds and the rates
of live birth (%) in EE2-treated mice was detected. Student’s t test for un-paired comparison
(two-sided) and Pearson correlation analysis were applied for statistical analysis. All the
data presented as mean ± SD and were analyzed via GraphPad Prism 9 software. A p value
of ≤0.05 was considered statistically significant.

Fig. 3. CCl4-induced liver injuries and PTB in mice. (A) The G.Ds, rates of PTB (%)
and live birth (%) in controls (n=9) and pregnant mice treated with 1.0 (n=5), 1.5 (n=9), or
2 mL kg−1 CCl4 (n = 5). (B) The sTBA levels in controls (n=9) and mice treated with 1.5
kg mL−1 CCl4 (n = 9) and a negative correlation between sTBA concentrations and G.Ds

53

or the rates of live birth (%). Student’s t test for un-paired comparison (two-sided) and
Pearson correlation analysis were applied for statistical analysis. All the data presented as
mean ± SD and were analyzed via GraphPad Prism 9 software. A p value of ≤0.05 was
considered statistically significant.

Fig. 4. Elevated serum AST levels in CCl4 -induced liver injuries and PTB in mice.
(A) Serum AST levels in control (n=9) and CCl4 -treated mice (n=9), and correlation
analyses between serum AST levels and G.Ds or the rates of live birth (%) and a direct
correlation between G.Ds and the rates of live birth (%) in the CCl4 -treated mice. (B) A
positive correlation between serum AST levels and sTBA concentrations was detected in
CCl4 –treated mice. Student’s t test for un-paired comparison (two-sided) and Pearson
correlation analysis were applied for statistical analysis. All the data presented as mean ±
SD and were analyzed via GraphPad Prism 9 software. A p value of ≤0.05 was considered
statistically significant.

Fig. 5. Bile acid cholic acid (CA) induced PTB in mice. (A) G.Ds and rates of PTB (%)
in control, 0.3% CA, 0.5% or 1% CA treated mice. (B) Rates of live birth (%) in control
(n=9) and mice treated with a diet containing 0.3% (n=6), 0.5% (n=8), or 1% CA (n=6)
and a positive correlation between G.Ds and rates of live birth (%). (C) The sTBA levels
in controls (n=9) and mice treated with 0.5% (n=8) or 1% CA diet (n=6) and a negative
correlation between sTBA levels and the G.Ds or the rates of live birth (%). Student’s t test
for un-paired comparison (two-sided) and Pearson correlation analysis were applied for
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statistical analysis. All the data presented as mean ± SD and were analyzed via GraphPad
Prism 9 software. A p value of ≤0.05 was considered statistically significant.

Fig. 6. Serum AST levels in BA induced PTB in mice. (A) Serum AST levels in control
(n=9), 0.5% CA (n=8) and 1% CA (n=6) and a direct positive correlation between serum
AST and sTBA levels. (B) A negative correlation between serum AST levels and G.Ds or
the rates of live birth (%) was detected in mice treated with CA containing diet (n=13).
Student’s t test for un-paired comparison (two-sided) and Pearson correlation analysis were
applied for statistical analysis. All the data presented as mean ± SD and were analyzed via
GraphPad Prism 9 software. A p value of ≤0.05 was considered statistically significant.

Fig. 7. Elevated BAs, not liver injury, induced PTB in mice. (A) sTBA and serum AST
levels in mice treated with 0.3% CA in diet (n=7) or DY268 (20mg kg-1) (n=7) and the
control group (n=9). (B) The G.Ds and rates of PTB (%) in control (n=9) and mice treated
with a combination of 0.3% CA and DY268 (n=8). (C) sTBA concentration in control
(n=9) and mice treated with a combination of 0.3% CA and DY268 (n=8). (D) serum AST
levels in control (n=9) and treatment group (0.3% CA + DY268; n=8). (E) Representative
hepatic histopathology of control and mice treated with 0.3% CA and DY268. Student’s ttest for un-paired comparison (two-sided) was applied for statistical analysis. All the data
presented as mean ± SD and were analyzed via GraphPad Prism 9 software. A p value of
≤0.05 was considered statistically significant.
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Fig. 8. Prevention of PTB by restoring BA homeostasis. (A) The G.Ds, the rates of PTB
(%) and live birth (%) in mice treated with CCl4 alone (1.5 ml kg−1) (n=9) or a combination
of CCl4 (1.5 ml kg−1) and FXR agonist GW4064 (50 mg kg−1; n=13). (B) The sTBA and
serum AST levels in mice treated with CCl4 alone (n=9) or a combination of CCl4 and
GW4064 (n=11) and a positive correlation between sTBA and serum AST levels. (C) The
relative expression levels of mRNAs for BSEP and CYP7A1 in mice treated with CCl4
(n=9) or a combination of CCl4 and GW4064 (n=11). (D) The relative expression levels of
mRNAs for SHP and FXR in mice treated with CCl4 (n=9) or a combination of CCl4 and
GW4064 (n=11). Student’s t-test for un-paired comparison (two-sided) and Pearson
correlation test were applied for statistical analysis. All the data presented as mean ± SD
and were analyzed via GraphPad Prism 9 software. A p value of ≤0.05 was considered
statistically significant.

Fig. 9. Correlation analyses in mice treated with a combination of CCl4 and GW4064.
(A) the sTBA levels negatively correlated with the G.Ds but not the rates of live birth (%)
in mice treated with CCl4 and GW4064 (n=10). (B) serum AST levels negatively correlated
with the G.Ds and the rates of live birth (%). (C) a positive correlation between the G.Ds
and the rates of live birth (%) was detected. Pearson correlation analysis was applied to
determine the correlation coefficient and associated p values.
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ABSTRACT
The association between elevated maternal serum total bile acid (sTBA) and
preterm birth (PTB) has been previously established, but the underlying mechanism how
BA trigger PTB is lacking. The best characterized receptors amongst the bile acid activated
receptor (BAR) are FXR and TGR5. So far, the understanding of the receptors through
which BA induce PTB is totally lacking. Although FXR (-/-) mice gave birth in the normal
range of gestation, the G.Ds were significantly reduced compared to WT mice, a PTB-like
phenotype. Such PTB-like phenotype is consistent with elevated sTBA levels in FXR (-/-)
mice. The results thus indicate that it is unlikely that BA induce PTB through FXR. On the
other hand, TGR5 antagonist, SBI-115 induced PTB, indicating that BA induces PTB via
TGR5. Moreover, incubation of human and mouse myometrium with C5a has been
demonstrated previously, that C5a is a uterotonic agent. In addition, C5aR1(-/-) mice were
protected against LPS-induced miscarriage. However, the role of C5a/C5aR1 signaling
pathway in BA induced PTB is unknown. In current study, we investigated the effect of
cholic acid (CA) on TGR5 and C5aR1 expression in vivo in mice and in vitro in myometrial
and endometrial cells. We found that CA had minimal effects on the overall expression of
TGR5 both in vivo and in vitro. On the other hand, CA significantly increased the mRNA
and protein expression levels of C5aR1 both in vivo and in vitro. Similarly, the serum and
amniotic fluid (A.F) concentrations of C5a, and serum concentration of IL-6 were
markedly increased in CA treated mice. In addition, CA and SBI-115 treatments increased
the mRNA and protein expressions of C5aR1 and cAMP concentrations in vitro. On the
contrary, treatment with a TGR5 agonist CCDC in vitro decreased the mRNA and protein
expressions of C5aR1 and cAMP concentration. Taken together, it was concluded that
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elevated BA concentration induced PTB via TGR5 regulated C5a/C5aR1 signaling
pathway which in response induced inflammatory responses via IL-6. Modulating
C5a/C5aR1 signaling pathway may represent a new approach to develop therapies to
prevent or delay PTB in pregnant women with liver disorders.
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INTRODUCTION
Preterm Birth (PTB) is among the complex challenges that confront obstetricians
and gynecologists. Despite considerable research and clinical advancements in
gynecology, approximately 1 in 10 newborns in the United States are born prematurely
each year

(1)

while, 15 million babies born prematurely annually, accounting PTB the

largest contributor to infant mortality and morbidity globally

(2, 3)

. In the United States,

each year the estimated economic burden of PTB tops $26 billion (4, 5). PTB is a syndrome
of multiple factorial etiologies (6) and the underlying pathophysiological mechanisms that
contribute to PTB are not fully understood. Synthetic progestin 17α-hydroxyprogesterone
caproate (17-OHPC; Makena) is the only approved FDA therapy for PTB prevention.
However, it proved ineffective to decrease PTB rates in women susceptible to spontaneous
PTB and had no beneficial impact on fetal survival rates (7). In response FDA recommended
its withdrawal from the market, which would currently leave the women prone to PTB
without any approved prophylactic treatment (8-11).
Although, various factors contribute to the pathogenesis of PTB, however, women
with various liver dysfunctions are at increased risk for PTB

(12-18)

. We previously

demonstrated that dysregulation of bile acid (BA) increased the risk for PTB in pregnant
subjects with different hepatic disorders (19). In addition, we elucidated the direct etiological
link between BA dysregulation and PTB and identified that it was the elevated BAs, not
liver injury, that induced PTB. Although, the association of elevated maternal serum total
bile acid (sTBA) and PTB has been reported previously

(13, 14, 20)

, but the underlying

pathophysiological mechanism how elevated BA trigger PTB is still unknown. Apart from
an essential role in nutrient absorption, BAs are ligands for various receptors collectively
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known as bile acid-activated receptor (BAR). The best characterized receptors among these
are FXR

(21-23)

and the G protein bile acid-activated receptor (GPBAR), also known as

TGR5 (24-26). So far, the understanding of the receptor(s) through which BA induce PTB is
totally lacking. Along with receptor identification, present study aimed to identify the
potential signaling pathway through which BA induced PTB.
The complement is an essential constituent of innate immune defense system but
increasing body of evidence suggested its various roles during gestation (27, 28). In fact, the
association of pregnancy itself with increased activation of the maternal complement
system is quite obvious (29), as elevated circulating complement factors in maternal plasma
and its deposits on placental tissues have been identified in both normal and complicated
pregnancies

(29-33)

. However, dysregulated, or excessive activation of the complement

system may lead to pregnancy complications, including miscarriage and PTB. There is
increasing clinical evidence that identified the excessive activation of the complement
system as a causative factor to induce PTB

(34)

. In addition, clinical studies revealed that

pregnant women with elevated plasma levels of complement factors are at increased risk
of spontaneous PTB (35-37).
C5a is a powerful pro-inflammatory anaphylatoxin synthesized in the liver after the
cleavage of complement component C5 and exerts its biological effect by binding to its
specific receptor C5aR1

(38-40)

. It has been reported previously that incubation of human

fetal and placental membranes with human recombinant C5a ex vivo resulted in
upregulation of pro-labor mediators (41). In addition, the potential of C5aR1 in LPS-induced
mouse model of PTB has been investigated (42). However, the role of C5a/C5aR1 signaling
pathway in BA induced PTB is unknown. Thus, present study hypothesized that BA may
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modulate C5a/C5aR1 signaling pathway through TGR5 in BA induced mouse model of
PTB.
PTB is a syndrome triggered by multiple mechanisms which are complex and
multi-factorial. In fact, an increasing number of risk factors seem to contribute to inducing
preterm labor

(43)

, and a common component among these factors is inflammation at the

maternal-fetal interface

(44)

. A growing body of evidence suggested that labor and

pregnancy have many hallmarks of an inflammatory reaction, characterized by the release
of complement components triggered inflammatory mediators (45), that contribute to uterine
contraction, cell chemotaxis, cervical ripening, metalloproteinases production, membrane
awaking and rupture, and eventually leading to the onset and progress of labor (46).
In this study, we investigated the regulatory effects of BA on C5aR1 expression
through TGR5 activation. Although, it is evident in the literature that BAs induced
placental inflammation by activating TGR5/NF-κB signaling pathway in intrahepatic
cholestasis of pregnancy

(47)

. However, our current understanding on the regulation of

C5aR1 expression by BA via TGR5 activation in a setting of PTB is limited. A previous
study identified the uterotonic potential of C5a, resulted in the upregulation of various prolabor mediators, such as IL-6, IL-8, prostaglandin F2a, prostaglandin E2 and pro-matrix
metalloproteinase-9 (41). Furthermore, a mouse model of PTB revealed a direct pathogenic
potential of C5a in preterm labor by triggering macrophage chemotaxis and
metalloproteinase release, leading to cervix distensibility in preterm labor, that was not
observed in term deliveries (48, 49).
In addition to traditional function in dietary fat emulsification

(50)

, recent studies

revealed the function of BAs as signaling molecules which increase cellular cAMP levels
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(51). Being a receptor for BAs, TGR5 is widely accepted to couple to Gαs proteins and
activate cAMP signaling pathways in several tissues

(52, 53)

. Indeed, it is well established

that activation of TGR5 by BAs causes TGR5 internalization, followed by the release of
Gα subunit, adenylate cyclase (AC) activation, and cAMP production (54). In fact, growing
body of evidence demonstrated that BAs trigger the elevation of cAMP (55, 56). Thus, present
study hypothesized that BA may activate TGR5 which in response will mediate its effect
via cAMP regulated C5a/CaR1 signaling pathway which ultimately will trigger
inflammatory responses to induce PTB. The findings of current study will open an avenue
for developing mechanism-based therapies to prevent or delay PTB in pregnant women
with various liver disorders.

MATERIALS AND METHODS
Chemicals and Reagents: Cholic acid, olive oil and TritonTM were purchased from Sigma
Aldrich. CCDC was purchased from ChemShuttle and MCE, MedChemExpress. SBI-115
was purchased from MedKoo Biosciences. DMSO and paraformaldehyde solution (4% in
PBS) were purchased from Santa Cruz Biotechnology. 1, 2 propanediol and corn oil were
purchased from Acros Organics. Mouse TBA kits (Cat # 12161338) and cAMP ELISA kits
(Lot # 10102164, 10102165, 1010269, and 10102173) were purchased from Cell Biolabs.
Mouse AST kits (Cat # 4D18K07530 and 4H30K0753) were purchased from Biovision.
Mouse/Rat Estradiol ELISA kit (Lot # ES180S-100) was purchased from Calbiotech and
progesterone ELISA kit (Lot # 0474261 and 0541421) was purchased from Cayman
Chemicals. Mouse Complement C5a ELISA kit (Lot # EK0987) was purchased from
Boster Biological Technology. 20X phosphate buffer saline (PBS) and 20X citrate buffer
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were purchased from Thermo Scientific. Mineral oil, hydrogen peroxide, xylene,
hematoxylin, and MEM (1X) and DMEM/F12 (1:1) (1X) were purchased from Fischer
Scientific.

Animal Experimentation General Care: All mice received humane care according to the
guidelines delineated in the “Guide for the Care and Use of Laboratory Animals” prepared
by the National Academy of Sciences

(57)

. All mice studies were performed with prior

approval by the Institutional Animal Care and Use Committee (IACUC) of the University
of Rhode Island with protocol number: AN09-02-008. All mice had free access to food and
water ad libitum and were kept in ventilated cages in a 12-h light – dark cycle, control
room temperature (20 – 22°C) and relative humidity (40%).

Timed Mating of Mice: CD-1 male and female mice of ages 5 to 8 weeks were purchased
from Charles River Laboratory (Wilmington, MA) and were acclimatized for one week
before starting any experimental study. Mice at the age of two to six months old were used
for mating. Two or three female mice were mated overnight with a male mouse to achieve
timed pregnancy. Next morning male mice were separated from females and this day was
considered gestation day (G.D 0). Similarly, WT (C57BL/6) (n=8; sourced from Charles
River and Jackson Laboratories) and FXR (-/-) mice (n=8; in house breeding) were also
used for timed mateing.

Treatment of CD-1 Pregnant Mice with 1% CA Diet: On G.D 15.3 one group of
pregnant mice (n=20) were treated with 1% CA in a regular chow diet and one group
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(n=10) was treated with regular chow diet to serve as a control. CA treatment was
continued for 48 hours. On G.D 17.3 both control and 1% CA treated mice were euthanized
and blood, amniotic fluid (A.F), uterus, placenta, and liver samples were collected. The
uterus, placenta and liver samples were immediately snapped frozen with liquid nitrogen
or fixed with 4% paraformaldehyde in PBS. In addition, another group of pregnant mice
(n=6) was treated with 1% CA diet, started on G.D 15.3 and continued till the mice gave
birth.

Treatment of Pregnant Mice with TGR5 Receptor Agonist and Antagonist: CD-1
pregnant mice were either treated with TGR5 agonist, CCDC (n=4) at a dose of 5 mg kg−1
or TGR5 antagonist, SBI-115 (n=6) at a dose of 15 mg kg−1 by oral gavage twice a day
started on G.D 14.7 and continued till the mice gave birth. Both CCDC and SBI-115 were
dissolved in corn oil and DMSO at a ratio of 9:1. In addition, one group of mice (n=7) was
treated with a combination of CCDC (started on G.D 14.7) and 1% CA (started on G.D
15.3) and the treatments continued till the labor.

Cell and Cell Culture: hTERT-HM (human myometrial) cell line was provided by Dr.
Jennifer C. Condon (School of Medicine, Wayne State University, Detroit, Michigan,
USA) and Ishikawa (human endometrial) cell line was purchased from Sigma Aldrich.
hTERT-HM cells were maintained in DMEM/F12 supplemented with 10% (v/v) FBS, 1%
(v/v) penicillin/streptomycin (P/S) and 1% (v/v) non-essential amino acids (NEAA).
Similarly, Ishikawa cells were maintained in MEM supplemented with 10% FBS, 1% P/S
and 1% NEAA. Both cell lines were maintained and grown in a 5% CO2 incubator at 37˚C.
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For the treatment, the cells were grown in 10 mL petri dishes and were treated for 48 hours
with either 0.1% DMSO, 100 µM CA, 100 µM CCDC or 100 µM SBI-115. After 48 hours,
mRNA or cell lysates were extracted for RT-PCR and Western blots respectively.

Serum TBA (sTBA) and Serum AST Assays: sTBA assay was performed according to
the manufacture’s protocol. In short, to collect the serum, blood samples collected from
euthanized mice was centrifuged at 2000 rpm for 15 minutes. The reaction was initiated by
adding 20 µL of the diluted BA standards or samples to the 96-microtiter plate followed
by the addition of 150 µL of assay reagent A to each well and incubated at 37 °C for 5
minutes. Then, 50 μL of assay reagent B was added to the standards and one half of the
paired samples while, 50 μL of NADH reagent was added to the other half of the paired
sample well. The plate was incubated at 37 °C for 60 minutes and the reading was taken at
a primary wavelength of 405 nm and a secondary wavelength of 630 nm via a
spectrophotometer. The data was analyzed as per kit’s instructions. For serum AST
detection, the assay reaction was initiated by the addition of 10 μL glutamate standards or
serum samples with 40 μL of assay buffer followed by the addition of 100 μL of reaction
mix (prepared per kit’s instructions). The plate was measured initially at 450 nm (A1) at
T1 (T1 > 10 minutes) and then again (A2) at T2 after incubating the reaction at 37 °C for
60 minutes. Glutamate standard curve was plotted, and AST activity or levels were
calculated according to kit instructions.

Pregnancy Hormones Assays: Mouse estradiol (E2) concentrations were measured
according to the manufacture’s Mouse/Rat Estradiol ELISA kit protocol. The reaction was
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initiated by dispensing 25 μL of standards or serum samples into appropriate wells
followed by the addition of 100 μL of working reagent of estradiol enzyme conjugate and
incubated at 25 °C for 2 hours. The plate was washed three times with 300 μL of 1X
washing buffer. Then, 100 μL of TMB reagent was dispensed into each well followed by
incubation at 25 °C for 30 min. The reaction was then stopped by the addition of 50 μL of
Stop Solution. The absorbance was read at 450 nm via spectrophotometer. Similarly,
progesterone (P4) concentrations were also measured according to the manufacture’s
protocol. All the reagents, standards and serum samples were prepared as per kit’s
instruction. The reaction was initiated by the addition of 100 μL ELISA buffer to nonspecific binding (NSB) wells and 50 μL to maximum binding (B0) wells. Then, 50 μL of
respective standards or samples were added to their specific assigned wells followed by the
addition of 50 μL of progesterone AChE tracer except to the total activity (TA) and blank
wells. Then, 50 μL of progesterone ELISA antiserum was added to each well except the
TA, the NSB, and the blank wells. The plate was then incubated for one hour at room
temperature. The plate was then rinsed five times with wash buffer followed by the addition
of 200 μL of ellman’s reagent to each well and 5 μL of tracer to the TA wells. The plate
was then developed in dark by incubating for 90 min. Then, the plate reading was taken
spectrophotometrically at a wavelength of 405 nm and the data were calculated according
to the kit’s instructions.

RNA-Sequencing: Total RNA extracted from uterus tissues using RNA-bee reagent was
supplied for RNA-sequencing to LC Science (Houston, Taxes, USA). Total RNA quality
and quantity were analyzed by Bioanalyzer 2100 and RNA 6000 Nano LabChip Kit
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(Agilent, CA, USA) with RIN number >7.0. Approximately 2 µg of total RNA was used
to isolate Poly (A) mRNA with poly-T oligo attached magnetic beads. Following
purification, the poly(A) mRNA fractions were fragmented into small pieces and reversetranscribed to create cDNA library using stand-specific library preparation by dUTP
method. The average insert size for the paired-end libraries was 300±50 bp and the pairedend 2×150bp sequencing was performed on a llumina Hiseq 4000 at LC Sciences. For
bioinformatics analysis, the raw data was cleaned via Cutadapt and perl scripts in house
software, mapped the genome through HISAT2, assembled the transcripts of each sample
independently through StrignTie software, all assemblies were merged via StringTie,
gffcompare and mRNAs expression was profiled through StrignTie. The expression level
of mRNAs was determined by calculating FPKM via StrignTie, and differentially
expressed mRNAs were determined through Rpackage - Ballgown software.

Mouse IL-6, TNF-α and Complement C5a ELISA: For the quantitation of mouse IL-6,
TNF-α and C5a, Mouse IL-6/Interleukin-6 ELISA kit (cat# EK0411), Mouse TNF
Alpha/Tumor necrosis factor ELISA kit (cat# EK0527) and Mouse Complement C5a
ELISA Kit (cat# EK0987) were purchased from Boster Biological Technology which all
have the same assay protocols. In short, all regents, respective working standards and
samples were prepared as directed in assay protocol. One hundred microliters of the
standards or samples were added to the assigned wells followed by the addition of 100 μL
of the sample diluent buffer and incubation at 37 °C for 90 min. Then, the liquid from all
the wells was discarded followed by the addition of 100 μL of 1x biotinylated anti-mouse
IL6 antibody, 1x biotinylated anti-mouse TNF antibody or 1x biotinylated anti-mouse C5
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antibody to their respective plates and incubated at 37 °C for 60 min. The plate was then
washed with 300 μL 1x wash buffer. Then, 100 μL of 1x avidin-biotin-peroxidase complex
was added into each well followed by incubation at 37 °C for 30 min. The plate was then
washed 5 times with 1x wash buffer. Then, 90 μL of the color developing reagent was
added into each well followed by incubation in the dark at 37 °C for 20 min. The reaction
was then stopped by the addition of 100 μL of stop solution and the absorbance was read
spectrophotometrically at 450 nm. The data was analyzed as per assay’s protocol.

TaqMan Quantitative Real-Time PCR: RNA extraction, cDNA synthesis, and TaqMan
RT-PCR assays were performed as previously described (manuscript 1). In short, RNA bee
reagent (RNA-STAT-60, Tel-Test, Inc,) was used for RNA extraction from tissue and cell
samples. For cDNA synthesis 2μg of total RNA was mixed with 1 μl random primers
followed by the addition of DEPC treated water to make the final volume of 13 μL. The
primers were annealed to RNA template at 65°C for 5 minutes followed by 1 minute
incubation on ice. Then, 7μL of RT reaction mix containing 4 μL 5x SSIV buffer,1 μL
0.1M DDT, 1 μL RNase inhibitor and 1 μL SuperScript IV Reverse Transcriptase (200
U/μL) was combined to the annealed RNA samples. Then, the combined reaction mixture
was incubated at 23 °C for 10 min followed by 50°C for 10 min. The reaction was then
terminated at 70°C for 10 min. The cDNA samples were then diluted six times with
autoclaved water. TaqMan universal master mix (Applied Biosystems) was used for realtime PCR reaction in a total volume of 10 μL, containing 5 μL of universal PCR TaqMan
master mix, 1.5 μL of autoclaved water ,0.5 μL of gene specific TaqMan probe and 3 uL
of cDNA templates. Applied Biosystems ViiA Real-Time PCR instrument was used for
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amplification. The cycling description was 50°C for 2 min, 95°C for 10 min, followed by
40 cycles of 15 s at 95°C and 1 min at 60°C. The TaqMan assay probes for mouse TGR5
(assay ID: Mm04212121_s1), human TGR5 (assay ID: Hs01937849_s1), mouse C5aR1
(assay ID: Mm00500292_s1), human C5aR1 (assay ID: Hs00704891_s1), mouse C5
(assay ID: Mm00439275_m1), mouse IL-6 (assay ID: Mm00446190_m1), mouse TNF-α
(assay ID: Mm00443258_m1) and human glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; lot# 1902046) and mouse GAPDH (lot# 2005049) were purchased from Applied
Biosystems. Transcript levels of TGR5, C5aR1, C5, IL-6 and TNF-α were normalized
against the GAPDH. Validated TaqMan probes and TaqMan master mixtures were
obtained from Applied Biosystems. Quantification was done through comparative CT
(∆CT) method normalized against housing keeping gene GAPDH.

Western Blotting: Approximately, 70-90 mg of uterus tissues were homogenized in 800
µL 1x ST buffer (composed of 0.25 M sucrose and 10 mM Tris-HCL; pH 7.4) and 8 µL of
HaltTM protease inhibitor cocktail (Thermo Scientific, Lot# VL316129). For cell lysis, 500
- 700 µL of 1x RIPA lysis buffer (consists of 50 mM Tris HCl, 150 mM NaCl, 1.0% (v/v)
NP-40, 0.5% (w/v) sodium deoxycholate, 1.0 mM EDTA, 0.1% (w/v) SDS and 0.01%
(w/v) sodium azide at a pH of 7.4) and 5 - 7 µL of protease inhibitor cocktail was used.
Fifty micrograms of total protein were loaded into their assigned wells. Membranes were
blotted with antibodies against rabbit anti-TGR5/GPAR1 (NBP2-23669; Novus
biologicals), mouse C5aR1 (CD88 (S5/1) (cat#: SC-53795, Santa Cruz Biotechnology).
The same membranes were stripped with restoreTM western blot stripping buffer (lot#
V5308530; Thermo Scientific) and re-blotted with antibodies against GAPDH (Cat#: SC-

73

365062, Santa Cruz Biotechnology) or mouse beta-actin (Cat#: SC-47778, Santa Cruz
Biotechnology). ClarityTM western ECL substrate (peroxidase solution; BIO-RAD) and
clarityTM western ECL substrate (luminol/enhancer solution; BIO-RAD) were added in
equal parts to membranes for chemiluminescent detection and incubated according to
protocol. Images were captured via

MYECL

Imager (Thermo Scientific). The expression

levels of target proteins were normalized against GAPDH or beta-actin and quantified via
ImageJ software while representative images from each group were presented.

Immunofluorescence: Fresh fixed uterus tissues were embedded in paraffin and affixed
onto the slides. The tissue slides were then deparaffinized three times in xylene for 5 min
each followed by rehydration in 100%, 95% and 70% ethanol twice for 10 min and then in
50% ethanol two times for 5 min each. The slides were then washed with DI water and
immersed in citrate buffer (pH 6.0) for 10 min at 95°C. After cooling the slides, they were
immersed in DI water for 3 min each, incubated in 3.0% H2O2 for 15 min to block
endogenous peroxidase activity and then washed again two times in DI water for 3 min.
To permeabilize the tissues, the sections were washed twice for 10 min with 1% animal
serum in PBS with 0.4% Triton X-100 (PBS-T). To block any non-specific binding the
tissues sections were then incubated in SuperBlockTM Blocking Buffer in PBS for 30 min
followed by staining with mouse C5aR1 (CD88 (S5/1) (cat#: SC-53795, Santa Cruz
Biotechnology) antibody in 1% serum PBS-T or Rabbit Pre-immune serum overnight at
4°C. The tissue sections were then washed twice in 1% serum PBS-T for 10 min each,
incubated with Anti-Mouse Alexa-Fluro 488 (GR3401602-1; Abcam) in 1% serum PBST for 1 hour and washed again twice in 1% serum PBS-T for 10 min each. For nuclear
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labelling, tissues sections were stained with DAPI for 5min, and then anti-fade mounting
medium was applied to the slides. The pictures were captured with Nikon Upright
Microscope (RI-INBRE) at 20X magnification.

Cyclic Adenosine Monophosphate (cAMP) Assay: Cell lysates were prepared as per
assay’s protocol (Lot # 10102164, Cell Biolabs). Initially, the medium was aspirated and
then lysis buffer was added to the cells, incubated at 4°C for 20 min. The cells were scraped
with cell scraper, transferred to centrifuge tubes, and centrifuged at 14000rpm for 10 min.
The supernatant was collected. Similarly, frozen tissues were homogenized in lysis buffer
(5-10 µL of lysis buffer for 1mg of tissue) and then centrifuged to collect the supernatant.
The assay was initiated by the addition of 50 µL of the standards or samples to the goat
anti-rabbit antibody coated plate followed by the addition of 25 µL diluted peroxidase
cAMP tracer conjugate, 50 µL of diluted rabbit anti-cAMP polyclonal antibody and
incubated at room temperature for 2 hours with shaking. The plate was washed 5 times
with 250 µL 1x wash buffer per well. Then, 100 µL of substrate solution was added to each
well and incubated at room temperature for 20 min. The reaction was stopped by the
addition of 100 µL of stop solution. Results were read immediately via spectrophotometer
at 450 nm. The cAMP concentration was calculated as per assay’s instructions.

Statistical Analysis: For statistical analysis, student’s t test for unpaired comparison (twosided) was applied for normally distributed data. The correlation coefficient (r) and
associated p values were determined by Pearson correlation analysis. All the data presented
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as mean ± SD were analyzed via GraphPad Prism 9 software and a p value of ≤0.05 was
considered statistically significant.

RESULTS
The effects of CA treatment on serum, uterus, and amniotic fluid TBA, and serum
AST levels.
As mentioned in the previous manuscript, the elevated sTBA directly induced PTB
in pregnant mice and sTBA concentration increased following CA administration (19). CA
supplemented diet (1% w/w) was started on G.D 15.3 and continued till the mice gave
birth. In the present study, CA diet (1%) was also initiated on G.D 15.3 and continued for
48 hours and the mice were euthanized on G.D 17.3 before showing any signs of labor. CA
supplementation increased sTBA concentration as shown in Fig. 1A. The average sTBA
increased significantly from 7.57 ± 1.52 µM in control mice (n=10) to 23.36 ± 3.42 µM in
mice (n=20) fed with 1% CA diet (**** p<0.0001). Consistent with elevated sTBA, the
levels of TBA also increased markedly in the uterine tissues and A.F of the CA treated
mice. As shown in Fig. 1B, the average uterine TBA levels increased significantly (***p
= 0.0008) from 6.36 ± 1.58 µg/mL in control mice (n=10) to 11.27 ± 3.5 µg/mL in CA
treated mice (n=10). Similarly, the TBA levels in A.F also increased significantly (****p
< 0.0001) from 6.66 ± 0.74 µM in control mice (n=10) to 8.83 ± 1.06 µM in mice treated
with 1% CA (n=10)(Fig. 1C). Moreover, serum AST levels increased significantly from
16.50 ± 3.19 U L-1 in control mice (n=10) to 29.02 ± 4.61 U L-1 in mice (n=20) fed with
1% CA diet (**** p<0.0001; Fig. 1D). Of note, the serum AST levels increased by CA
treatment are within normal physiological range, suggesting that minimal hepatic injury
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caused by CA treatment. The findings indicate that it is the elevated BA and not the liver
injury itself that induces PTB.

Effects of CA treatment on serum estrogen and progesterone levels.
Among estrogens, estradiol (E2) is the predominant pregnancy hormone which
increases in the late stages of pregnancy

(58)

. Present study investigated whether BA

supplementation has any effects on serum estrogen E2 levels as compared to control mice.
As shown in Fig. 2A, serum E2 levels increased significantly (*p = 0.0274) from 20.20 ±
7.46 pg/mL in control mice (n=10) to 29.66 ± 9.97 pg/mL in 1% CA treated mice (n=10).
In fact, an elevated serum E2 level has been observed in patients with high BA levels (59).
On the contrary, BA treatment did not significantly change serum P4 levels (p = 0.228;
Fig. 2A), indicating that the process of parturition has not initiated yet. The decline in
circulating levels of this hormone that accompanies the onset of labor suggests that
progesterone withdrawal is critical for uterine contractility leading to labor (60). However,
when sTBA (n=20) was correlated with serum E2 (n=10) or serum P4 levels (n=10), no
correlation was observed between sTBA and serum E2 (r = 0.545; p = 0.103) or serum P4
levels (r = -0.124; p = 0.733) as shown in Fig. 2B. Taken together, the data demonstrated
that CA supplementation increased serum E2 level but had minimal effect on serum P4
level.

BA induced PTB in mice through TGR5, and not FXR.
To further confirm our previous findings (manuscript 1) that BA treatment induces
PTB, we carried out additional study by treating CD-1 pregnant mice (n=6) with 1% CA
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supplemented diet. In line with our previous data, BA successfully induced PTB. As shown
in Fig. 3A, the mean G.Ds were markedly decreased (****p < 0.0001) from 19.90 ± 0.44
days (n=9; data shown in manuscript 1) to 18.29 ± 0.44 days (G.Ds combined with G.Ds
shown in manuscript 1) in mice treated with 1% CA supplemented diet (n=12). The data
thus firmly established that elevated BA induce PTB, supporting our previous finding
(manuscript 1) that elevated sTBA is the triggering factor to induce PTB.
BAs are ligands for various bile acid-activated receptors (BAR). The two best
characterized receptors among these are FXR

(21-23)

and TGR5

(24-26)

. So far, the

understanding of receptor(s) through which BA induce PTB is unknown. To understand
such underlying mechanism, we carried out experiments to determine whether BA induce
PTB through FXR or TGR5. First G.Ds in WT (C57BL/6) and FXR (-/-) mice were
determined. It is well evident in the literature, that FXR (-/-) mice exhibit elevated sBA
concentrations

(61-64)

. We hypothesized that if FXR signaling is involved in BA induced

PTB, then PTB will not be observed in FXR (-/-) mice. Despite of the fact that the G.Ds in
FXR-/- mice are still in the range of normal birth as PTB is considered before G.Ds 18.9,
but the mean G.Ds were markedly decreased (*p = 0.016) from 19.53 ± 0.33 days in WTmice (n=8) to 19.07 ± 0.33 days in FXR (-/-) mice (n=8; Fig. 3B). Hence, our data
demonstrated that FXR was not involved in the induction of PTB by BA. Thus, we
proposed that it might be TGR5 signaling pathway that is involved in BA induced PTB.
To test such assumption, we carried out studies by treating CD-1 pregnant mice
with either TGR5 agonist CCDC (5mg/kg twice daily, oral gavage) or TGR5 antagonist
SBI-115 (15mg/kg twice daily, oral gavage). It was reasoned that TGR5 agonism will
either induce or delay PTB and vice versa results were expected with TGR5 antagonism.
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As shown in Fig. 3C, the mean G.Ds were comparable (p = 0.102) between CCDC treated
mice (n=4) and control mice (n=9). However, when pregnant mice were treated with a
combination of 1% CA and CCDC, the mean G.Ds were slightly increased from 18.29 ±
0.44 days in 1% CA mice (n=12) to 18.64 ± 0.75 days in mice (n=7) treated with a
combination of CA and CCDC without reaching statistical significance (Fig. 3D). On the
other hand, SBI-115 treatment induced PTB because the G.Ds significantly decreased
(****p < 0.0001) from 19.90 ± 0.44 days in control mice (n = 9) to 18.84 ± 0.10 days in
SBI-115 treated mice (n=6), indicating that CA and SBI-115 treatments might follow the
same mechanistic pathway in inducing PTB. Taken together, our data suggested that it was
TGR5, not FXR, through which BA induced PTB in pregnant mice.

CA treatment did not change TGR5 expression both in vivo and in vitro.
Based upon above demonstrated data that TGR5 signaling pathway is involved in
BA induced PTB. Such findings were further explored at both mRNA and proteins levels
to determine whether BA has any effect on the overall expression of TGR5. RNA-seq data
revelated that CA treatment did not change TGR5 expression. The FPKM of TGR5 in
control mice (n=4) was comparable to CA treated mice (n=4) as shown in Fig. 4A (p =
0.082). Consistent with the findings from RNA-Seq data, CA treatment had limited effects
on TGR5 expression at both mRNA and proteins levels. TGR5 expression at mRNA level
detected by real-time PCR did not change significantly (p = 0.740) in CA treated mice
(n=20) when compared with control mice (n=10; Fig. 4A). Consistent with the results of
TGR5 mRNA expression, western blot revealed that TGR5 protein expression at uterus
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tissue level did not change markedly in CA treatment group when compared with control
(Fig. 4B).
To determine whether CA acts similarly in vitro as in vivo, the effects of CA
treatment (100 µM) on TGR5 expression was investigated in hTERT-HM (human
myometrial) and Ishikawa (endometrial) cells. Treatment with CA had limited effects on
TGR5 expression in both cell lines because TGR5 expression at mRNA levels were
comparable between controls and CA treated hTERT-HM and Ishikawa cells with p-values
of 0.780 and 0.247 respectively (Fig. 4C). The findings demonstrated that BA only
activated TGR5 receptor, speculating that agonist only activate the receptor, and it is
unlikely that the expression of the receptor itself changes by agonist binding. The data thus
firmly established that CA treatment did not change TGR5 expression both in vivo and in
vitro.

CA treatment increased the levels of C5 in liver, and C5a in serum and amniotic fluid
(A.F).
Present study aimed to uncover the underlying mechanism by which BA induced
PTB. We carried out a mouse study by euthanizing the mice on G.D 17.3 before the
initiation of labor. RNA seq (data not shown) revealed potential target genes differentially
expressed between control (n=4) and CA treated mice (n=4). Among the altered genes, we
identified C5aR1 as a potential target gene involved in BA induced PTB. C5a/C5aR1
signaling pathway plays a functional role in the complement system activation. C5a is a
pro-inflammatory anaphylatoxin synthesized after cleavage of C5 and exerts its biological
action by binding to its specific receptor C5aR1
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(65, 66)

. Considering the fact, that liver is

the main site of C5 synthesis (67), we first detected mRNA expression of C5 in liver tissues.
CA treatment significantly (*p = 0.032) increased C5 mRNA levels in CA treated mice (n
= 20) when compared with control mice (n = 10; Fig. 5A).
After identifying that C5 expression increased at mRNA level by CA treatment, we
next carried out experiments to determine whether CA has any effect on C5a concentrations
in serum and A.F. As shown in Fig. 5B, serum C5a concentrations increased significantly
from 418.0 ± 144.7 pg/mL in control mice (n=10) to 553.9 ± 121.1 pg/mL in mice (n=20)
fed with 1% CA diet (* p=0.012). Similarly, A.F C5a concentrations increased significantly
from 786.4 ± 329.9 pg/mL in control mice (n=10) to 1105.0 ± 372.1 pg/mL in mice (n=20)
fed with 1% CA diet (* p=0.012). In support of present findings, it has been reported that
elevated concentrations of C5a has been detected in the A.F of women with PTB due to
microbial invasion of the amniotic activity

(37)

. In fact, human and mouse myometrium

incubated with C5a showed increased frequency of contractions, suggesting that C5a is a
uterotonic molecule (68, 69).

CA treatment increased the expression of C5aR1 both in vivo and in vitro.
The role of the C5aR1, in both miscarriage and PTB has been investigated in a
bacterial endotoxin murine model

(70)

. However, no studies have been conducted to

investigate the effect of CA on C5aR1 expression in a mouse model of PTB. In the present
study, C5aR1expression in mice uterus tissues was detected by RNA-Seq which was
differentially expressed in CA treated mice when compared with control mice. The FPKM
of C5aR1 increased significantly (*p = 0.023) in CA treated mice (n=4) when compared to
control mice (n=4; Fig. 6A). Consistent with the findings from RNA-Seq data, CA
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treatment significantly increased (***p = 0.0002) C5aR1 expression at mRNA level
detected by real-time PCR in CA treated mice (n=20) when compared with control mice
(n=10; Fig. 6A). In accord with the altered mRNA levels, CA treatment increased the
protein levels of C5aR1expression detected by western blot (Fig. 6B). Quantification of
C5aR1 via ImageJ revealed that CA treatment (n=20) has significantly high (**p = 0.009)
C5aR1 expression at protein levels when compared with control (n=10; Fig. 6B). In
addition, we also carried out immunofluorescence to detect C5aR1 expression at uterus
tissue level. As shown in Fig. 6C, 1% CA treated tissues have relatively higher staining
when compared with controls.
To determine whether CA acts similarly in vitro as in vivo, the effects of CA
treatment on C5aR1 expression was investigated in hTERT-HM and Ishikawa cells. The
data demonstrated that CA (100 µM) treatment increased significantly C5aR1 expression
detected by real-time PCR in hTERT-HM (*p = 0.0114) and Ishikawa cells (*p = 0.0290)
when compared with their respective 0.1% DMSO groups (Fig. 6D). Consistent with the
results of mRNA levels, C5aR1 protein levels detected by western blot were increased
significantly (*p = 0.015; Fig. 6E) in Ishikawa cells as well in hTERT-HM cells (*p =
0.049; Fig. 6F) following CA (100 µM) treatment. Taken together, the results revealed that
CA treatment increased C5aR1 expression both in vivo and in vitro.

TGR5 and C5aR1 transcripts were repressed in the late stages of pregnancy.
In current study, the expression levels of TGR5 and C5aR1 in uterine tissues were
detected on G.D 17.3. However, our understanding of how gestation affects TGR5 and
C5aR1 signaling pathway in normal pregnancy is lacking. Thus, to determine the dynamics
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TGR5 and C5aR1 expressions in the uterine tissues during the normal pregnancy, the
expression levels of TGR5 and C5aR1 were detected before pregnancy, G.D 3.3, G.D 10.3,
G.D 17.3, and after labor. As shown in Fig. 7A, TGR5 expression at mRNA level severely
reduced on G.D 10.3 (****p < 0.0001), G.D 17.3 (****p < 0.0001), and after birth (***p
< 0.001) when compared with non-pregnant and G.D 3.3. However, such decline increased
significantly (***p=0.001) after birth when compared with G.D 17.3.
The expression levels of C5aR1 were also significantly reduced on G.D 10.3
(****p < 0.0001), G.D 17.3 (****p < 0.0001), and after birth (**p=0.0011) when
compared with non-pregnant and G.D 3.3 (Fig. 7B). However, unlike TGR5 expression,
C5aR1 expression was increased significantly (****p < 0.0001) on G.D 17.3 when
compared with G.D 10.3. On the other hand, C5aR1 expression increased significantly
(****p<0.0001) after birth when compared with G.D 17.3. Taken together, for the first
time the dynamics of TGR5 and C5aR1 expression at mRNA levels were determined in
pregnant mice during the entire pregnancy. The data indicated that TGR5 and C5aR1
transcripts were severely repressed in the late stages of pregnancy.

CA treatment increased the level of IL-6, but not TNF-alpha.
As illustrated, the levels of C5a in serum and A.F, and the expression of C5aR1 in
uterus tissues were increased by CA treatments. In fact, C5a is one of the most potent
inflammatory mediators, and plays a pivotal role in pro-inflammatory functions by
inducing its effects through C5aR1

(71)

. In addition, it has been demonstrated that

C5a/C5aR1 signaling contributes to the pathogenesis of inflammatory diseases

(72, 73)

. To

determine whether CA had any potential to induce C5a/C5aR1 downstream inflammatory
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responses, we detected IL-6 and TNF-alpha concentrations in the serum and A.F, and their
mRNA expressions in uterus tissues. Our data demonstrated that serum IL-6 concentrations
increased significantly (**p = 0.0067) in CA treated mice (n=10) when compared with
control mice (n=10; Fig. 8A). However, such increase of IL-6 concentrations in A.F did
not reach statistical significance (p = 0.272; Fig. 8A). On the other hand, TNF-alpha
concentrations were comparable between CA treatment and control group in both serum (p
= 0.167) and A.F (p = 0.287) as shown in Fig. 8B.
Furthermore, we performed real-time PCR to detect the expression of IL-6 and
TNF-alpha mRNA levels in uterus tissues following CA treatment. We found that mRNA
levels of IL-6 increased significantly (*p = 0.045) in CA treated mice (n=20) when
compared with control mice (n=10; Fig. 8C). On the other hand, the expression of TNFalpha at mRNA level also increased in CA treated mice (n=20) when compared with
control mice (n=10). However, such increase did not reach a statistical significance (p =
0.094; Fig. 8D). The data demonstrated that in the setting of BA induced PTB, CA
treatment triggered inflammatory responses via IL-6.

Effects of TGR5 agonist and antagonist on TGR5 and C5aR1 expression in vitro.
Based upon the earlier demonstrated findings, that TGR5 agonist CCDC had
minimal effects on 1% CA induced PTB (Fig. 3D) while, TGR5 antagonist SBI-115
induced PTB (Fig. 3E). To investigate the effects of CCDC and SBI-115 on TGR5 and
C5aR1 expression in vitro, we carried out experiments in hTERT-HM and Ishikawa cells
by treating them with CCDC (100 µM) or SBI-115 (100 µM). The expression of TGR5
and C5aR1 mRNA levels were detected by real-time PCR. As shown in Fig. 9A, mRNA
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levels of TGR5 were comparable between CCDC and DMSO group in both hTERT-HM
and Ishikawa cells with p values of p = 0.367 and p = 0.473 respectively. On the contrary,
SBI-115 treatment significantly decreased the expression of TGR5 at mRNA levels in both
HTERT-HM (*p = 0.0460) and Ishikawa cells (*p = 0.027) when compared to their
respective DMSO groups (Fig. 9A). Taken together, the data suggested that TGR5 agonist
had minimal effects on TGR5 mRNA expression as compared to its antagonist which
significantly reduced the mRNA expression of TGR5.
In addition, we have shown earlier that CA treatment increased the expression of
C5aR1in vitro in both hTERT-HM and Ishikawa cells (Fig. 6D). To determine whether
CCDC or SBI-115 had also any effect in modulating C5aR1 expression, the effects of
CCDC or SBI-115 treatments on C5aR1 expression was investigated in both hTERT-HM
and Ishikawa cells. We found that CCDC (100 µM) treatment significantly decreased the
expression of C5aR1 at mRNA levels in both HTERT-HM (***p = 0.0001) and Ishikawa
cells (**p = 0.003) when compared to their respective 0.1% DMSO groups (Fig. 9B). On
the contrary, SBI-115 (100 µM) treatment significantly increased the expression of C5aR1
at mRNA level in Ishikawa cells (*p = 0.0383) when compared with 0.1% DMSO (Fig.
9B). Although, such increase did not reach statistical significance (p = 0.766) in hTERTHM cells when compared with 0.1% DMSO (Fig. 9B).
In line with the results of mRNA levels, C5aR1 protein levels detected by western
blot were decreased significantly (*p = 0.013) in CCDC (100 µM) treated and increased
significantly (*p = 0.048) in SBI-115 (100 µM) treated Ishikawa cells when compared with
their respective 0.1% DMSO groups (Fig. 9C). Taken together, the effect of SBI-115 in
inducing PTB (Fig. 3E) may be attributed to the fact that SBI-115 increased the expression
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of C5aR1 through TGR5 regulation. Thus, it is concluded that CCDC and SBI-115
differentially regulated C5aR1 expression through TGR5 agonism or antagonism.

Effects of CA treatment on cAMP levels in vivo, and effect of CA, CCDC and SBI-115
on cAMP levels in vitro.
In the current study, we identified that BA induced PTB in mice through activation
of TGR5. In fact, TGR5 activation by BA is usually described as coupled with cAMP
production in a number of cell types

(74)

. An increasing body of evidence revealed that

stimulation of TGR5 by BA leads to the activation of a stimulatory G-protein resulting in
a rise in intracellular levels of cAMP which in turn activates the cAMP regulated
downstream signaling

(75, 76)

. As a measurement of TGR5 downstream activity, cAMP

levels were assessed in the uterine tissues of mice. We found that there was a slight increase
in cAMP levels in CA treated mice when compared with control. However, such increase
was not statistically significant (p = 0.629). On the contrary, cAMP concentration was
significantly increased (****p < 0.0001) in CA (100 µM) treated Ishikawa cells when
compared with 0.1% DMSO treated cells (Fig. 10B).
To further investigate the effects of TGR5 agonist and antagonist on cAMP
production, we performed a series of experiments. First, we determined whether activation
of TGR5 by a synthetic agonist CCDC has any effect on cAMP production. We expected
that CCDC will increase the cAMP concentration in the same way as CA treatment did.
However, contrary to our expectations, CCDC (100 µM) treatment reduced significantly
(***p = 0.0005) the cAMP levels in Ishikawa cells when compared with 0.1% DMSO (Fig.
10C). As expected, (based on the CCDC cAMP data) treatment by a synthetic antagonist
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SBI-115 had opposite effect on cAMP levels. SBI-115 (100 µM) treatment increased
significantly (****p < 0.0001) the cAMP levels in Ishikawa cells when compared with
0.1% DMSO (Fig.10D).

Discussion
In the context of PTB, we previously identified a direct etiological link between
elevated BA and PTB and demonstrated that liver dysfunctions characterized by increased
levels of BA increased the risk for PTB

(19)

. However, the underlying signaling pathway

through which BA triggered PTB was not explored. In the present study, we showed that
BA induced PTB via TGR5 activation, and not FXR signaling pathway. Our findings
revealed that BA markedly increased the expression of C5aR1 at mRNA and protein levels
both in vivo and in vitro, identifying a novel mechanistic insight into the pathogenesis of
PTB induced by BA. In our previous findings, we showed that sTBA directly corelated
with the G.Ds, demonstrating a direct etiological link between BA and PTB. Well
consistent with our previous data, sTBA levels were markedly high in CA treated mice. In
addition, we observed a similar trend in uterus and A.F, as both exhibited elevated levels
of TBA. The results represented the first description of TBA levels in A.F and uterus tissues
in a mouse model of PTB. Our new findings indicate that along with sTBA, measuring
TBA levels in A.F in pregnant women can also potentially serve as biomarker for
predicting PTB in pregnant women with liver disorders.
Along with receptor identification, present study aimed to identify the potential
signaling pathway through which BA induced PTB. Based on RNA-seq data, we identified
C5aR1 a potential targeted gene, differentially expressed by CA treatment when compared
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with the control. The expression of C5aR1 has been described predominantly on the
myeloid cells, including monocytes, macrophages, neutrophils, eosinophils, and basophils
(77-82)

. However, a growing body of evidence indicate that other cells such as smooth muscle

cells, epithelial cells, and endothelial cells also express C5aR1 (83-91). Although, C5aR1 in
placental tissues has been reported previously in a LPS-induced mouse model of PTB. The
data indicated that C5aR1 knock out mice were protected against LPS-induced miscarriage
however, the absence of C5aR1 had minimal effect on the rates of PTB (42). Currently, no
studies have investigated the expression of C5aR1 in uterus tissues in an in vivo mice model
of PTB as well in myometrial and endometrial cell lines.
The complement system is considered as a key immune regulator for cell and tissue
homeostasis

(92)

. It is well established that during complement activation, C5 is

enzymatically cleaved in the liver and give rise to the anaphylatoxin C5a. This proinflammatory peptide execute its biological effects by interacting with C5aR1

(93)

. In the

present study, we found that mRNA level of C5 in liver tissues were higher in CA treated
mice when compared with the control. To support our findings, the role of BA-induced
complement activation has been linked to chronic hepatitis C, and fibrosis in a murine
model of toxic liver injury

(94)

. In addition, increased levels of C5a had been reported in

women with serve preeclampsia (95). To determine whether C5a can be found at circulating
level, we measured the concentration of C5a in serum. Consistent with the effects on C5
mRNA levels in liver, CA markedly increased the concentration of C5a in serum. The
findings were fortified by the elevated C5a levels in A.F in CA treated mice when
compared with the control. In support of our findings, elevated C5a concentrations has
been documented in the A.F of women with preterm labor and intra-amniotic infection by
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microbial invasion

(37)

. Indeed, incubation of human and mouse myometrium with C5a

demonstrated increased frequency of contractions, implying that C5a is a uterotonic agent
(68, 69)

. Taken together, the data indicated that elevated C5a concentration may induce the

process of parturition due to its uterotonic potential.
In addition, we found that CA supplementation markedly increased the expression
of C5aR1 at both mRNA and protein levels, indicating that BA induced PTB via C5aR1
signaling pathway. In line with in vivo data, the C5aR1 expression was also markedly high
in vitro at both mRNA and protein levels, when cells were treated with CA, indicating that
BA can increase the expression of C5aR1 in myometrial and endometrial cells. In support
of our findings, a previous study demonstrated that LPS-induced miscarriage was averted
in C5aR1 (-/-) mice when compared with WT-mice

(70)

. However, knocking down of

C5aR1 had minimal effects on the rates of PTB, when mice were treated with LPS in late
gestation. These findings are in direct contrast to another study, reporting that C5aR1 (-/-)
mice were resistant to LPS-induced PTB (49). It is noteworthy, that LPS-induced PTB and
BA induced PTB represents two different mice models of PTB, and probably the
underlying mechanisms may differ. However, accumulating evidence and findings of the
current data indicate the direct involvement of C5aR1 in the process of labor and parturition
in the setting of PTB. In support of such notion, it has been demonstrated that
administration of C5aR1 synthetic antagonist, PMX53 alleviated the pro-labor mediators
(41)

. Taken together, our novel findings indicate that C5aR1 signaling pathway contribute

to the pathogenesis of PTB.
Currently, our understanding of how gestation affects TGR5 and C5aR1 signaling
pathway in normal pregnancy is lacking. In this study the dynamics of TGR5 and C5aR1

89

expression were investigated in vivo in pre-pregnant and pregnant mice on day-3, day-10,
day -17, and after labor. The findings indicated that both TGR5 and C5aR1 transcription
were markedly repressed in the later stages of pregnancy. Albeit, the gene expression of
TGR5 has been shown to be repressed in the placenta’s of ICP patients and in a rat model
(96)

of obstructive cholestasis

. One possible explanation is that increased production of

estrogen and progesterone in the later stages of pregnancy may repress the expression of
TGR5 and C5aR1. However, to fully understand, why the dynamics of TGR5 and C5aR1
decreased in late stages of pregnancy, more mechanistic studies are required.
It has been widely recognized that pregnancy and labor are characterized by various
hallmarks of inflammatory responses. In fact, pro-inflammatory mediator actively
participate in the conversion of uterus from a quiescent phase to a more contractile state
(97-100)

, indicating their potential to promote labor by stimulating uterine contractility and

cervical ripening

(101-103)

. Indeed, rodent models of PTB has been established by

administration of pro-inflammatory stimuli in the uterus and cervix

(104-106)

. Although,

anaphylatoxins are identified to elicit pro-inflammatory actions (107), especially C5a and its
receptor C5aR1 are involved in various inflammatory disease

(108)

. However, our

understanding is limited of how TGR5 regulated C5a/C5aR1 signaling pathway contributes
to the downstream inflammatory cascade to initiate the process of labor. In the current
study, we found that serum IL-6 were increased in CA treated mice when compared with
control, indicating that BA induced PTB also involved inflammatory reactions via IL-6.
Our findings build on prior studies, implicating the elevation of pro-inflammatory
cytokines, notably IL-6 and IL-1β in the uterus, A.F, and placenta prior to PTB (109-111). In
the current study we did not observe a significant increase in the concentration of IL-6 in

90

A.F, One possible explanation is that we euthanized the mice well before the onset of labor.
Thus, it is speculated that the inflammatory responses at this point have not been initiated
at the fetal-maternal interface.
Currently, our understanding is limited regarding the potential roles of TGR5
agonists and antagonists in the pathogenesis of PTB. In the current study, TGR5 agonism
with CCDC did not change the expression of TGR5 at mRNA level in both myometrial
and endometrial cells. Contrary to the effects of CCDC, TGR5 antagonist SBI-115
markedly decreased the expression of TGR5 in both cell lines. Our findings are in accord
with a previous published data, where SBI-115 decreased the protein expression of TGR5
in the loperamide induced constipation in rats

(112)

. In addition, the increase in C5aR1

expression by SBI-115 in both myometrial and endometrial cells demonstrate that SBI-115
have the potential to induce PTB. Our postulation is in line with the mice data as SBI-115
induced PTB (Fig. 3E).
It is well documented that binding of BAs to TGR5 is linked with the accumulation
of intracellular cAMP followed by activation of their downstream signaling pathways (113).
However, in current study, we did not observe a marked increase in cAMP levels in vivo
in uterus tissues of CA treated mice. On the contrary, increased in cAMP levels were
observed in vitro in endometrial cells. One possible explanation for such discrepancy in
uterus tissues and endometrial cells is the difference in the duration of treatments. The mice
were fed with CA diet for 48 hours as compared to in vitro cells which were treated only
for 1 hour. In fact, many GPCRs emanated signals fade over time and results in attenuated
response to repeated stimulation with same agonist, indicating the desensitization of
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GPCRs (114, 115). Indeed, cAMP response is so quick and occurs either in seconds or minutes,
which might not be directly mediated by transcriptional regulation (24).
A growing body of evidence has identified well defined signaling effects for Gproteins, such as adenyl cyclase (AC). In fact, both Gαs (stimulatory) and Gαi (inhibitory)
subunits of G-proteins can regulate ACs. Gαs subunit stimulates AC to convert ATP into
cAMP. Elevated cAMP mediates the activation of cAMP regulated proteins, like protein
kinase A. On the contrary, Gαi can inhibit certain isotypes of ACs resulting in reduced
cAMP levels

(116)

. Accumulated data have suggested that TGR5 agonists increased the

intracellular cAMP levels

(117, 118)

. However, in the present study, CCDC reduced while

SBI-115 increased the intracellular cAMP levels. One possible explanation for such
discrepancy is that CCDC-binding to TGR5 may recruit Gαi subunit of G-protein, resulting
in decreased cAMP levels. On the other hand, SBI-115 increased cAMP levels by
promoting Gαs recruitment. In support of our speculation, it has been reported previously
that TGR5 agonist in ciliated cholangiocytes decreased and in non-ciliated cholangiocytes
increased the cAMP levels, and the opposite effects of TGR5 agonist were attributed to the
coupling of TGR5 to Gαi in ciliated cells and Gαs in non-ciliated cells (119).
In summary, it is concluded that BA activated TGR5 which in response mediated
its effect via cAMP regulated C5a/C5aR1 signaling pathway, which ultimately triggered
inflammatory responses to induce PTB. However, more mechanistic studies are needed to
fully support this conclusion. The findings from current study accompanied by mechanistic
insights may provide the molecular basis for developing new therapies to prevent or delay
PTB through modulating C5a/C5aR1 signaling pathway in women with different liver
disorders due to their increased susceptibility to PTB.
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FIGURE LEGENDS

Fig. 1. Effects of CA treatment on serum, uterus, and amniotic fluid (A.F) TBA, and
serum AST levels. (A) sTBA levels in control pregnant mice (n=10) and 1% CA pregnant
mice (n=20). (B) Uterus TBA levels in control pregnant mice (n=10) and 1% CA pregnant
mice (n=10). (C) A.F TBA levels in control pregnant mice (n=10) and 1% CA pregnant
mice (n=10). (D) serum AST levels in control pregnant mice (n=10) and 1% CA pregnant
mice (n=20). Student’s t test for un-paired comparison (two-sided) was applied for
statistical analysis. All the data presented as mean ± SD and were analyzed via GraphPad
Prism 9 software. A p value of ≤0.05 was considered statistically significant.

Fig. 2. Effects of CA treatment on serum estrogen and progesterone levels. (A) Serum
E2 and serum P4 levels in control pregnant mice (n=10) and 1% CA pregnant mice (n=10).
(B) No correlation was detected between sTBA and serum E2 or serum P4 levels. Student’s
t test for un-paired comparison (two-sided) and Pearson correlation analysis were applied
for statistical analysis. All the data presented as mean ± SD and were analyzed via
GraphPad Prism 9 software. A p value of ≤0.05 was considered statistically significant.

Fig. 3. BA induced PTB in mice through TGR5, and not FXR. (A) G.Ds in control
(n=9) and 1% CA treated mice (n=12). (B) G.Ds in C57BL/6 mice (n=8) and FXR (-/-)
mice (n=8). (C) G.Ds in control (n=9) and CCDC treated mice (n=4). (D) G.Ds in 1% CA
(n=12) and 1% CA + CCDC treated mice (n=7). (E) G.Ds in control (n=9) and SBI-115
treated mice (n=6). Student’s t test for un-paired comparison (two-sided) was applied for
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statistical analysis. All the data presented as mean ± SD and were analyzed via GraphPad
Prism 9 software. A p value of ≤0.05 was considered statistically significant.

Fig. 4. CA treatment did not change TGR5 expression both in vivo and in vitro. (A)
Uterus FPKM of TGR5 in control (n=4) and 1% CA (n=4), and relative TGR5 mRNA
levels in control pregnant mice (n=10) and 1% CA pregnant mice (n=20). (B) Protein
expression of TGR5 were detected by western blot in control and 1% CA uterus tissues
and were quantified by ImageJ. (C) Relative TGR5 mRNA levels in hTERT-HM
(myometrial) and Ishikawa (endometrial) cells in 0.1% DMSO (n=8) and 1% CA (n=8)
treatment groups. Student’s t test for un-paired comparison (two-sided) was applied for
statistical analysis. All the data presented as mean ± SD and were analyzed via GraphPad
Prism 9 software. A p value of ≤0.05 was considered statistically significant.

Fig. 5. CA treatment increased the levels of C5 in liver, and C5a concentrations in
serum and amniotic fluid. (A) Relative C5 mRNA levels in liver of control pregnant mice
(n=10) and 1% CA pregnant mice (n=20). (B) Serum and A.F C5a concentrations in control
pregnant mice (n=10) and 1% CA pregnant mice (n=20). Student’s t test for un-paired
comparison (two-sided) was applied for statistical analysis. All the data presented as mean
± SD and were analyzed via GraphPad Prism 9 software. A p value of ≤0.05 was considered
statistically significant.

Fig. 6. CA treatment increased the expression of C5aR1 both in vivo and in vitro. (A)
Uterus FPKM of C5aR1 in control (n=4) and 1% CA (n=4) and relative C5aR1 mRNA
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levels in control pregnant mice (n=10) and 1% CA pregnant mice (n=20). (B) C5aR1
expression at protein levels were detected by western blot in control pregnant mice (n=10)
and 1% CA pregnant mice (n=20) and C5aR1 expressions were quantified through ImageJ.
(C) Representative immunofluorescence staining with goat anti-mouse C5aR1 IgG. (D)
Relative C5aR1 mRNA levels in hTERT-HM and Ishikawa cells in 0.1% DMSO (n=8)
and 1% CA (n=8) treatment groups. (E) Western blot of C5aR1 expression in endometrial
cells, and (F) myometrial cells in 0.1% DMSO and CA (100 µM) treatments groups and
their quantifications were done via ImageJ. Student’s t test for un-paired comparison (twosided) was applied for statistical analysis. All the data presented as mean ± SD and were
analyzed via GraphPad Prism 9 software. A p value of ≤0.05 was considered statistically
significant.

Fig. 7. TGR5 and C5aR1 transcripts were repressed in the late stages of pregnancy.
(A) Relative TGR5 mRNA levels in non-pregnant (n=5) and pregnant mice on G.D-3
(n=5), G.D-10 (n=7), G.D-17 (n=10), and after labor (n=9). (B) Relative C5aR1 mRNA
levels in non-pregnant (n=5) and pregnant mice on G.D-3 (n=5), G.D-10 (n=7), G.D-17
(n=10), and after labor (n=9). Student’s t test for un-paired comparison (two-sided) was
applied for statistical analysis. All the data presented as mean ± SD and were analyzed via
GraphPad Prism 9 software. A p value of ≤0.05 was considered statistically significant.

Fig. 8. CA treatment increased the level of IL-6 but not TNF-alpha. (A) Serum and
A.F IL-6 levels in control pregnant mice (n=10) and 1% CA pregnant mice (n=10). (B)
Serum and A.F TNF-alpha levels in control pregnant mice (n=10) and 1% CA pregnant

122

mice (n=10). (C) Relative mRNA levels of IL-6, (D) and relative mRNA levels of TNFalpha in control pregnant mice (n=10) and 1% CA (BB) pregnant mice (n=20). Student’s t
test for un-paired comparison (two-sided) was applied for statistical analysis. All the data
presented as mean ± SD and were analyzed via GraphPad Prism 9 software. A p value of
≤0.05 was considered statistically significant.

Fig. 9. Effects of TGR5 agonist and antagonist on TGR5 and C5aR1 expression in
vitro. (A). Relative TGR5 mRNA levels in 0.1% DMSO (n=6), 100 µM CCDC (n=6), and
100 µM SBI-115 (n=4) in hTERT-HM and endometrial Ishikawa cells. (B) Relative C5aR1
mRNA levels in 0.1% DMSO (n=6), 100 µM CCDC (n=6), and 100 µM SBI-115 (n=4) in
hTERT-HM and Ishikawa cells. (C) Western blot of C5aR1 expression in CCDC (100 µM)
and SBI-115 (100 µM) treated Ishikawa cells by comparing with their respective 0.1%
DMSO treated groups. Protein expression for C5aR1 were quantified through ImageJ.
Student’s t test for un-paired comparison (two-sided) was applied for statistical analysis.
All the data presented as mean ± SD and were analyzed via GraphPad Prism 9 software. A
p value of ≤0.05 was considered statistically significant.

Fig. 10. Effects of CA treatment on cAMP levels in vivo, and effect of CA, CCDC and
SBI-115 on cAMP levels in vitro. (A) Uterus cAMP levels in control pregnant mice (n=10)
and 1% CA pregnant mice (n=20). (B) cAMP levels in Ishikawa cells treated with 0.1%
DMSO (n=7) and 100 uM CA (n=7). (C) cAMP levels in Ishikawa cells treated with 0.1%
DMSO (n=7) and 100 uM CCDC (n=7). (D) cAMP levels in Ishikawa cells treated with
0.1% DMSO (n=7) and 100 uM SBI-115 (n=7). Student’s t test for un-paired comparison
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(two-sided) was applied for statistical analysis. All the data presented as mean ± SD and
were analyzed via GraphPad Prism 9 software. A p value of ≤0.05 was considered
statistically significant.
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